Care of Paraplegic Patients in Critical Care

 

Care of Paraplegic Patients in Critical Care: A Comprehensive Review

Dr Neeraj Manikath , Claude.ai

Abstract

Paraplegic patients present unique challenges in the critical care setting, requiring a multidisciplinary approach that addresses both acute medical complications and long-term functional outcomes. This review examines evidence-based strategies for managing paraplegic patients in the ICU, focusing on respiratory management, cardiovascular stability, prevention of secondary complications, and optimization of neurological recovery. We present practical clinical pearls and lesser-known insights to enhance the care of this vulnerable population.

Introduction

Paraplegia, defined as motor and/or sensory impairment of the lower extremities with trunk involvement, most commonly results from traumatic spinal cord injury (SCI), though non-traumatic etiologies including vascular events, infections, and neoplasms account for increasing proportions of cases.[1,2] The global incidence of traumatic SCI ranges from 10.4 to 83 per million population annually, with approximately 50% resulting in paraplegia.[3]

Critical care management of paraplegic patients extends beyond the immediate post-injury period, as these patients frequently require ICU admission for acute medical complications throughout their lifetime. Understanding the pathophysiology of SCI and its systemic effects is crucial for optimizing outcomes in this population.

Pathophysiology of Spinal Cord Injury

Primary and Secondary Injury

The initial mechanical trauma causes primary injury through direct compression, contusion, or laceration of neural tissue.[4] This is followed by a cascade of secondary injury mechanisms including:

• Vascular disruption and hemorrhage
• Ischemia and hypoxia
• Excitotoxicity from glutamate release
• Ionic dysregulation and cellular edema
• Inflammation and oxidative stress
• Apoptosis

Pearl #1: The concept of the "golden hour" in SCI is increasingly recognized as the "platinum 24 hours." While earlier intervention is preferred, the secondary injury cascade continues for days to weeks, creating multiple therapeutic windows.[5]

Neurogenic Shock vs. Spinal Shock

These two distinct entities are frequently confused:

Neurogenic shock is a form of distributive shock resulting from loss of sympathetic tone below the injury level, characterized by:

• Hypotension without compensatory tachycardia
• Warm, well-perfused extremities
• Occurs primarily in injuries above T6

Spinal shock refers to transient loss of all neurological function below the injury level, including:

• Areflexia
• Flaccid paralysis
• Loss of autonomic function
• Duration: hours to weeks (average 4-6 weeks)

Oyster #1: The return of the bulbocavernosus reflex traditionally marked the end of spinal shock, but this concept has been refined. The delayed plantar reflex is now considered a more reliable indicator, appearing approximately 1-3 days post-injury.[6]

Initial Critical Care Management

Hemodynamic Management

Blood Pressure Goals: Current guidelines recommend maintaining mean arterial pressure (MAP) ≥85-90 mmHg for 7 days following acute SCI to optimize spinal cord perfusion.[7]

Hack #1: The "Rule of 90s"

• Maintain MAP ≥90 mmHg
• Keep SpO2 ≥90%
• Avoid PaCO2 <35 or >45 mmHg
• Target urine output ≥0.5 mL/kg/h

These targets create an optimal physiological environment for neurological recovery.

Vasopressor Selection:

• First-line: Norepinephrine (provides both α and β-adrenergic stimulation)
• Second-line: Dopamine (particularly if bradycardia is prominent)
• Avoid: Pure α-agonists like phenylephrine in isolation (may worsen bradycardia through baroreceptor reflex)

Pearl #2: Consider atropine at bedside for the first 48-72 hours. Unopposed vagal tone can cause profound bradycardia, especially during suctioning or position changes. Prophylactic atropine (0.5-1 mg) before these procedures can prevent cardiac arrest.[8]

Respiratory Management

Respiratory complications are the leading cause of morbidity and mortality in paraplegic patients.[9]

Level-Specific Respiratory Impact:

• T1-T6: Moderate impairment (abdominal muscles affected)
• T7-T12: Mild impairment (lower abdominal muscles affected)
• Below T12: Minimal respiratory impact

Pulmonary Management Strategies:

1. Aggressive Pulmonary Hygiene:

   • Assisted cough techniques (quad cough)
   • Mechanical insufflation-exsufflation devices
   • Regular position changes (q2h minimum)
   • Early mobilization protocols

2. Mechanical Ventilation Considerations:

   • Use lung-protective strategies (tidal volume 6-8 mL/kg ideal body weight)
   • PEEP optimization (typically 5-8 cmH2O)
   • Early weaning protocols with spontaneous breathing trials

Hack #2: The "Abdominal Binder Technique" When transitioning paraplegic patients to upright positions, apply an abdominal binder before elevation. This compensates for lost abdominal muscle tone, improves diaphragmatic function by preventing visceral sagging, and can increase vital capacity by 10-15%.[10]

Oyster #2: Glossopharyngeal breathing (frog breathing) is a rarely taught technique where patients use their pharyngeal muscles to gulp air into the lungs. Teaching this technique to appropriate patients can provide up to 1000 mL of additional tidal volume and serve as a backup if ventilator support is temporarily unavailable.[11]

Neurological Assessment and Monitoring

Standardized Assessment: The International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) examination should be performed:

• Initially
• At 72 hours
• Prior to discharge
• At follow-up intervals

Monitoring for Neurological Deterioration: Serial examinations are critical as up to 20% of patients deteriorate within the first week.[12]

Red flags for deterioration:

• Ascending sensory level
• Development of upper extremity weakness (in paraplegics)
• Worsening respiratory function
• New-onset severe pain

Pearl #3: Don't forget the digital rectal examination. It provides crucial information about sacral sparing, which has significant prognostic implications. The presence of any sensory or motor function in the lowest sacral segments (S4-S5) indicates an incomplete injury with better recovery potential.[13]

Prevention and Management of Complications

Venous Thromboembolism (VTE)

Paraplegic patients have a 9-100% incidence of DVT without prophylaxis, with 10-15% developing PE.[14]

Prophylaxis Strategy (Multimodal):

1. Mechanical Prophylaxis:

   • Sequential compression devices immediately
   • Consider inferior vena cava filter for contraindications to anticoagulation

2. Pharmacological Prophylaxis:

   • Low molecular weight heparin (Enoxaparin 40 mg SC daily or 30 mg SC q12h)
   • Start within 72 hours if no contraindications
   • Continue for minimum 8-12 weeks (some recommend 3 months)

3. Surveillance:

   • Weekly lower extremity doppler ultrasound for first 4 weeks
   • High clinical suspicion (remember: classic signs may be absent)

Hack #3: The "Calf Warmth Check" In paraplegic patients, traditional DVT signs are unreliable. Develop a habit of comparing calf warmth daily during examination. Unilateral warmth without visible trauma has high sensitivity for DVT in this population and should prompt immediate imaging.[15]

Oyster #3: Consider adjusted-dose anticoagulation (higher than prophylactic, lower than therapeutic) for high-risk patients: those with complete motor paraplegia, history of VTE, or additional risk factors. Some centers use enoxaparin 40 mg SC twice daily for these patients, though this is not universally standardized.[16]

Pressure Injury Prevention

Pressure injuries develop in 20-60% of SCI patients, with critical care stays significantly increasing risk.[17]

Comprehensive Prevention Strategy:

1. Surface Selection:

   • Advanced pressure redistribution surfaces (not just "air mattresses")
   • Specialty beds for high-risk patients (alternating pressure, low air loss)

2. Repositioning Protocol:

   • Every 2 hours minimum
   • Document exact position and time
   • Use 30-degree lateral positioning (not 90-degree)
   • Float heels completely off bed surface

3. Skin Inspection:

   • Twice daily minimum
   • Use mirrors for self-inspection when able
   • Special attention to bony prominences

4. Nutritional Optimization:

   • Protein 1.25-1.5 g/kg/day
   • Vitamin C 500-1000 mg daily
   • Zinc supplementation if deficient
   • Consider arginine supplementation (controversial but some evidence)[18]

Pearl #4: The "Two-Finger Rule" When repositioning, ensure you can easily slide two fingers between any bony prominence and the support surface. If you cannot, the patient needs repositioning or surface adjustment. This simple check can prevent Stage I pressure injuries from ever developing.

Hack #4: Prophylactic Barrier Film Apply transparent barrier film to high-risk areas (sacrum, ischial tuberosities, heels, lateral malleoli) immediately upon ICU admission. This provides an additional protective layer and makes skin inspection easier. Reapply every 3-5 days.[19]

Autonomic Dysreflexia (AD)

A potentially life-threatening complication occurring in injuries above T6, though can occur as low as T10.

Pathophysiology: Noxious stimuli below the injury level → sympathetic discharge → vasoconstriction below lesion → severe hypertension → baroreceptor activation → parasympathetic response above lesion → bradycardia (but vasodilation cannot occur below lesion)

Clinical Presentation:

• Severe hypertension (>20-40 mmHg above baseline)
• Pounding headache
• Facial flushing and diaphoresis above lesion
• Piloerection ("goosebumps")
• Bradycardia or tachycardia
• Blurred vision, nasal congestion

Management Algorithm:

1. Immediate Actions:

   • Sit patient upright (if safe)
   • Loosen tight clothing/devices
   • Check blood pressure every 5 minutes

2. Identify and Remove Trigger (most common → least common):

   • Bladder distension (40%) - catheterize or irrigate existing catheter
   • Fecal impaction (30%) - perform rectal examination (use lidocaine jelly)
   • Skin irritation/pressure
   • Tight clothing or devices
   • Ingrown toenails, fractures
   • Acute abdomen, renal calculi

3. Pharmacological Management (if BP remains elevated after trigger removal):

   • First-line: Short-acting antihypertensives
     • Nifedipine immediate-release 10 mg PO (bite and swallow)
     • Captopril 25 mg PO/SL
   • Second-line (ICU setting):
     • Nitropaste 2% (1-2 inches above lesion) - easily removed
     • Labetalol 10-20 mg IV
     • Hydralazine 10-20 mg IV

Pearl #5: Always use topical anesthetic (lidocaine gel) before any procedure below the injury level, even if the patient has no sensation. This can prevent triggering autonomic dysreflexia. Wait 5-10 minutes after application before proceeding.[20]

Oyster #4: Autonomic dysreflexia can be triggered by labor and delivery in pregnant paraplegic women. These patients should have epidural anesthesia placed early in labor, even if they report no pain, to prevent AD episodes.[21]

Neurogenic Bowel Management

Bowel complications cause significant morbidity and impact quality of life.

Classification:

• Upper motor neuron bowel (injury above conus medullaris): Reflexive bowel, preserved anal tone, tends toward constipation
• Lower motor neuron bowel (injury to conus/cauda equina): Areflexic bowel, decreased/absent anal tone, tends toward incontinence

Management Protocol:

1. Initial Phase (ICU):

   • Nothing per rectum (NPR) for first 3-7 days if possible
   • Rectal tube placement can worsen pressure injury risk
   • Low fiber diet initially
   • Consider polyethylene glycol for constipation

2. Bowel Program Development:

   • Establish regular schedule (same time daily, usually morning)
   • Use stimulants 30 minutes prior:
     • Digital stimulation
     • Suppositories (bisacodyl 10 mg or glycerin)
     • Mini-enemas if needed
   • Allow adequate time (30-60 minutes)
   • Position appropriately (slight forward lean if possible)

3. Pharmacological Adjuncts:

   • Stool softeners (docusate)
   • Osmotic laxatives (polyethylene glycol)
   • Prokinetics (consider metoclopramide)
   • Avoid: Bulk-forming agents initially (can worsen impaction)

Hack #5: The "ABCDs of Bowel Management"

• Adequate hydration (1.5-2 L/day)
• Bowl program consistency (same time daily)
• Chemical stimulation (suppository/digital)
• Diet modification (progress fiber gradually)
• Safety (always use anesthetic gel for procedures)

Pearl #6: Abdominal massage can significantly improve bowel evacuation. Massage in a clockwise pattern (following the colon) for 10-15 minutes before the bowel program. Some studies show up to 50% improvement in bowel evacuation time.[22]

Neurogenic Bladder Management

Bladder dysfunction is universal in acute paraplegia and significantly impacts long-term outcomes.

Acute Phase Management:

1. Avoid Indwelling Catheters When Possible:

   • Intermittent catheterization (IC) is preferred
   • Frequency: q4-6h, target volume <400-500 mL per catheterization
   • If IC not feasible: use indwelling with strict protocols

2. Bladder Volume Monitoring:

   • Bladder scanner use q4-6h
   • Prevent overdistension (>500 mL) which can cause permanent detrusor damage

3. Fluid Management:

   • Target 1.5-2 L/day
   • Distribute throughout day (avoid large evening intake)
   • Monitor for autonomic dysreflexia during catheterization

Pearl #7: When initiating intermittent catheterization, use a "bladder training" approach even in the acute phase. Gradually increase intervals between catheterizations while monitoring post-void residuals. This may help preserve reflex bladder function and reduce long-term dependence on catheterization.[23]

Hack #6: Prophylactic Antibiotic Strategy Routine antibiotic prophylaxis for catheterization is NOT recommended (promotes resistance). However, a single dose of trimethoprim-sulfamethoxazole or nitrofurantoin before the first few catheterizations in a patient new to IC may reduce colonization. After that, only treat symptomatic UTIs.[24]

Spasticity Management

Spasticity develops in 65-78% of SCI patients, typically after spinal shock resolution.[25]

Beneficial vs. Problematic Spasticity: Not all spasticity is bad. Mild spasticity can:

• Maintain muscle bulk
• Reduce osteoporosis
• Improve venous return
• Assist with transfers

Indications for Treatment:

• Interferes with function or care
• Causes pain
• Triggers autonomic dysreflexia
• Impairs sleep
• Causes contractures

Management Hierarchy:

1. Address Noxious Stimuli:

   • UTI, constipation, pressure injuries
   • Tight clothing, positioning issues
   • Pearl #8: Always look for a trigger before adding medications. Treating spasticity pharmacologically while ignoring an ingrown toenail is treating the symptom, not the cause.

2. Non-Pharmacological:

   • Regular stretching (twice daily minimum)
   • Positioning and splinting
   • Cold/heat application
   • Aquatic therapy when appropriate

3. Pharmacological:

   • First-line: Baclofen (start 5 mg TID, titrate slowly)
     • Monitor for withdrawal if discontinued abruptly
   • Second-line: Tizanidine (start 2 mg qHS, increase gradually)
   • Third-line: Diazepam, gabapentin, dantrolene
   • Refractory: Consider intrathecal baclofen pump

4. Interventional:

   • Botulinum toxin injections for focal spasticity
   • Phenol/alcohol nerve blocks
   • Surgical options (rarely needed)

Oyster #5: The "baclofen taper" principle: Never stop baclofen abruptly, even if the patient is NPO for a procedure. Baclofen withdrawal can cause seizures, hallucinations, and even death. If oral intake is not possible, use nasogastric administration or consider IV diazepam as a temporary bridge.[26]

Pain Management

Pain affects 65-85% of SCI patients and is often undertreated.[27]

Pain Classification in SCI:

1. Nociceptive Pain:

   • Musculoskeletal (overuse, positioning)
   • Visceral (kidney stones, bowel distension)
   • Treatment: NSAIDs, acetaminophen, opioids if severe

2. Neuropathic Pain:

   • At-level: Nerve root compression, can be sharp/shooting
   • Below-level: Central neuropathic pain, often burning/dysesthetic
   • Treatment: Gabapentinoids, tricyclics, SNRIs

3. Mixed/Other:

   • Spasticity-related
   • Complex regional pain syndrome

Comprehensive Pain Management Strategy:

Hack #7: The "Multimodal Pain Ladder" for SCI Build your regimen from multiple classes simultaneously rather than sequentially:

• Foundation: Scheduled acetaminophen (avoid NSAIDs long-term due to SCI complications)
• Neuropathic: Gabapentin or pregabalin (titrate slowly)
• Mood/Sleep: Tricyclic antidepressant (amitriptyline 10-25 mg qHS) - dual benefit
• Spasticity component: Baclofen or tizanidine
• Breakthrough: Short-acting opioid (minimize use)
• Interventional: Consider early referral for nerve blocks, spinal cord stimulation

Pearl #9: Positioning is often overlooked as pain management. Proper wheelchair fit, cushion selection, and bed positioning can reduce pain by 30-40% without medications. Consult physical and occupational therapy early.[28]

Oyster #6: Tramadol should be used with extreme caution or avoided in SCI patients. It has serotonergic properties and can lower seizure threshold. Given that SCI patients are already at increased seizure risk (especially with certain injury patterns) and often on other serotonergic medications, the risk-benefit ratio is unfavorable.[29]

Cardiovascular Considerations

Orthostatic Hypotension: Common due to loss of sympathetic tone and muscle pump function.

Management:

• Gradual position changes
• Compression garments (thigh-high stockings, abdominal binder)
• Adequate hydration
• Pharmacological: Midodrine (start 2.5 mg TID, increase as needed)
• Fludrocortisone in refractory cases

Bradycardia: May require temporary pacing in severe cases, particularly in the acute phase.

Pearl #10: The "tilt table progression" protocol for mobilization:

• Day 1: 15 degrees for 10 minutes
• Day 2: 30 degrees for 15 minutes
• Day 3: 45 degrees for 20 minutes
• Progress as tolerated, monitor BP continuously This gradual approach reduces syncope and improves tolerance.[30]

Heterotopic Ossification (HO)

Abnormal bone formation in soft tissues, occurs in 20-30% of SCI patients.[31]

Risk Factors:

• Complete injury
• Spasticity
• Pressure injuries
• Prolonged immobilization

Clinical Presentation:

• Decreased range of motion (often first sign)
• Swelling, warmth, erythema
• Can mimic DVT or infection
• Most commonly affects hips, knees, shoulders, elbows

Diagnosis:

• Elevated alkaline phosphatase (early, non-specific)
• X-ray (may not show until 3-4 weeks)
• Bone scan (sensitive, can detect early)
• CT scan (definitive for mature HO)

Management:

• Prevention: Early mobilization, range of motion exercises
• Acute phase: NSAIDs (indomethacin 75 mg daily) - controversial due to bleeding risk
• Established HO: Maintain ROM, surgical excision only after maturation (12-18 months)

Hack #8: If a paraplegic patient develops acute unilateral leg swelling, order BOTH a doppler ultrasound AND an alkaline phosphatase. If ultrasound is negative but alkaline phosphatase is elevated, suspect early HO and obtain imaging. This dual approach prevents missing either diagnosis.[32]

Nutritional Management

Nutritional needs change significantly after SCI due to altered metabolism and body composition changes.

Acute Phase (First 2 Weeks):

• Hypermetabolic state
• Caloric needs: 20-25 kcal/kg actual body weight
• Protein: 1.5-2.0 g/kg/day
• Early enteral nutrition (within 48-72 hours)

Subacute/Chronic Phase:

• Hypometabolic state develops
• Caloric needs: 22-24 kcal/kg ideal body weight
• Protein: 1.2-1.5 g/kg/day
• Adjust for activity level and injury level

Micronutrient Considerations:

• Vitamin D: Nearly universal deficiency, supplement 800-2000 IU daily
• Calcium: 1000-1200 mg daily, but monitor for nephrolithiasis
• Vitamin C: 500-1000 mg daily for wound healing
• Zinc: 15-30 mg daily if deficient
• B vitamins: Especially if on metformin (B12) or anticonvulsants (folate)

Pearl #11: The "SCI metabolic paradox": Despite lower caloric needs long-term, protein requirements remain high to preserve lean body mass. This means a higher protein-to-calorie ratio than standard recommendations.[33]

Hack #9: Early Probiotic Supplementation Emerging evidence suggests that early probiotic administration (within first week) may reduce C. difficile infection rates and improve bowel program success. Consider Lactobacillus rhamnosus GG or Saccharomyces boulardii supplementation.[34]

Psychological and Cognitive Considerations

Acute Stress Response:

• Common and expected
• Screen for depression and anxiety weekly
• Early psychology/psychiatry consultation

Delirium Prevention: Paraplegic patients are at high risk due to:

• Medications (opioids, benzodiazepines, anticholinergics)
• Sleep disruption
• Immobility
• Acute stress

Prevention Strategies:

• ABCDEF bundle adaptation:
  • Assess and manage pain
  • Both spontaneous awakening and breathing trials
  • Choice of analgesia and sedation
  • Delirium monitoring
  • Early mobility (adapted to abilities)
  • Family engagement

Pearl #12: The "orientation board" strategy: Place a large whiteboard at eye level with date, location, care team names, and daily goals. Update daily during rounds with patient involvement. This simple intervention can reduce delirium by 20-30%.[35]

Temperature Regulation

Poikilothermia (inability to regulate temperature) occurs with injuries above T6 due to loss of hypothalamic control over cutaneous vasculature.

Management:

• Monitor core temperature closely
• Environmental temperature control critical
• Layer clothing for adjustability
• Be cautious with heating/cooling devices (cannot sense discomfort)

Hack #10: The "Core Temperature Protocol" For patients with high thoracic injuries:

• Check core temperature q4h for first week
• Maintain ambient temperature 22-24°C (72-75°F)
• Use forced-air warming during procedures
• Educate on lifelong temperature management needs[36]

Mobilization and Rehabilitation

Early Mobilization Benefits:

• Reduced pressure injury risk
• Improved respiratory function
• Better cardiovascular tolerance
• Psychological benefits
• Prevention of contractures and HO

ICU Mobilization Pathway:

1. Phase 1 (Days 1-3):

   • Passive range of motion
   • Positioning changes
   • Sitting at edge of bed (if stable)

2. Phase 2 (Days 4-7):

   • Tilt table progression
   • Active-assisted upper extremity exercises
   • Transfer training initiation

3. Phase 3 (Week 2+):

   • Wheelchair mobility
   • ADL training
   • Strengthening program

Safety Criteria for Mobilization:

• Spinal precautions cleared or external stabilization adequate
• MAP >65 mmHg (can use vasopressors with activity)
• SpO2 >90% on ≤FiO2 0.6
• No uncontrolled arrhythmias
• Hemoglobin >7 g/dL

Pearl #13: "Mobility rounds" as a separate entity from medical rounds can increase mobilization success. A focused 15-minute multidisciplinary discussion (nurse, PT, OT, MD) specifically about mobility goals and barriers can improve mobility by 40%.[37]

Special Populations

Geriatric Paraplegic Patients

Older patients face unique challenges:

• Higher complication rates
• Slower recovery
• More comorbidities
• Polypharmacy concerns

Modifications:

• Lower BP targets (MAP 80-85 mmHg may be adequate)
• More aggressive DVT prophylaxis
• Earlier consideration of tracheostomy
• Comprehensive geriatric assessment
• Medication reconciliation with deprescribing when appropriate

Pediatric Considerations

Children have unique needs:

• Different injury patterns (SCIWORA more common)
• Growth plate considerations
• Family-centered care essential
• Age-appropriate psychological support
• Educational planning

Oyster #7: Spinal cord injury without radiographic abnormality (SCIWORA) is more common in children due to greater spinal elasticity. MRI is essential even with normal plain films and CT if clinical suspicion exists.[38]

Pregnant Paraplegic Patients

Pregnancy after SCI is increasingly common and generally safe with proper management.

Considerations:

• Increased VTE risk - prophylactic anticoagulation often warranted
• Autonomic dysreflexia risk increases in third trimester
• Labor may not be felt - monitor for preterm labor
• Epidural anesthesia recommended early in labor
• Cesarean section rates higher but not mandatory

Prognostic Factors and Neurological Recovery

Favorable Prognostic Indicators:

• Incomplete injury (any sacral sparing)
• Lower injury level
• Younger age
• Early motor recovery
• Higher initial ASIA motor score

Recovery Patterns:

• Most recovery occurs in first 3-6 months
• Continued improvements possible up to 18-24 months
• Upper extremity recovery better than lower in cervical injuries
• Motor recovery better than sensory

ASIA Impairment Scale (AIS) Conversion Rates:

• AIS A → B: ~10-15%
• AIS B → C: ~30-40%
• AIS C → D: ~60-70%
• AIS D → E: ~80-90%

Pearl #14: Early MRI findings can predict recovery. The presence of hemorrhage predicts worse outcomes, while edema-only patterns suggest better recovery potential. The Brain and Spinal Injury Center score combines MRI findings with clinical parameters for prognostication.[39]

Emerging Therapies and Future Directions

Current Evidence-Based Interventions:

• High-dose methylprednisolone remains controversial (not currently recommended by most guidelines)
• MAP augmentation (as discussed)
• Early surgical decompression (within 24 hours when indicated)

Promising Investigational Approaches:

• Epidural stimulation for motor recovery
• Activity-based rehabilitation
• Stem cell therapies
• Neuroprotective agents
• Brain-computer interfaces
• Exoskeleton technology

Oyster #8: The "discomplete" SCI concept: Recent research shows that even in "complete" injuries, some spared fibers may exist below the injury level (detected only by specialized electrophysiology). These patients may benefit from specific intensive therapies targeting these pathways, suggesting our classification system may need refinement.[40]

Quality Metrics and Outcomes

Key Performance Indicators for SCI Critical Care:

• Pressure injury incidence (goal: <5%)
• VTE rate with prophylaxis (goal: <5%)
• VAP rate (goal: <2 per 1000 ventilator days)
• ICU length of stay
• Time to mobilization
• Time to rehabilitation facility transfer
• ASIA score at discharge vs. admission

Bundle Compliance: Create institution-specific "SCI care bundles" including:

• Hemodynamic optimization
• VTE prophylaxis
• Pressure injury prevention
• Bowel/bladder program
• Early mobilization
• Psychological screening

Hack #11: The "SCI Daily Goals Checklist" Create a laminated checklist for bedside use:

• □ MAP goal achieved?
• □ Repositioned per protocol?
• □ Respiratory hygiene completed?
• □ VTE prophylaxis given?
• □ Bladder management per protocol?
• □ Bowel program if due?
• □ Skin inspection completed?
• □ Mobilization attempted?
• □ Pain assessment and management?
• □ Family communication completed?

Check completion during multidisciplinary rounds.[41]

Conclusion

The care of paraplegic patients in the critical care setting demands a comprehensive, multidisciplinary approach that addresses both immediate life-threatening complications and long-term functional outcomes. Key principles include aggressive prevention of secondary complications, early mobilization, standardized protocols for bowel and bladder management, and vigilant monitoring for autonomic dysfunction.

Success in managing these complex patients requires not only technical expertise but also attention to often-overlooked details—the clinical pearls and hacks that distinguish good care from excellent care. By implementing evidence-based protocols, maintaining high index of suspicion for complications unique to this population, and focusing on rehabilitation from the moment of ICU admission, we can optimize both survival and quality of life for our paraplegic patients.

The field continues to evolve, with emerging technologies and therapies offering hope for improved outcomes. However, the fundamentals of excellent critical care—meticulous attention to detail, prevention of complications, and individualized patient-centered care—remain paramount.

Key Clinical Pearls Summary

1. Platinum 24 hours - Multiple therapeutic windows exist
2. Prophylactic atropine - Have at bedside for procedures
3. Digital rectal exam - Critical prognostic information
4. Two-finger repositioning rule - Simple pressure injury prevention
5. Always anesthetize - Prevent autonomic dysreflexia triggers
6. Treat the trigger, not spasticity - Look for underlying causes
7. Bladder training early - May preserve reflex function
8. Positioning as analgesia - Often overlooked pain management
9. Dual diagnostic approach - DVT vs. HO in leg swelling
10. Higher protein-to-calorie ratio - SCI metabolic paradox
11. Core temperature monitoring - Critical in high thoracic injuries
12. Mobility-specific rounds - Separate from medical rounds
13. MRI prognostication - Hemorrhage vs. edema patterns
14. SCI daily checklist - Systematic approach prevents omissions

Recommended Reading and Resources

Guidelines:

• AANS/CNS Guidelines for Management of Acute Cervical Spine and Spinal Cord Injuries
• Consortium for Spinal Cord Medicine Clinical Practice Guidelines
• International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI)

---

References 

1. Sekhon LH, Fehlings MG. Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine (Phila Pa 1976). 2001;26(24 Suppl):S2-12.

2. New PW, Marshall R. International Spinal Cord Injury Data Sets for non-traumatic spinal cord injury. Spinal Cord. 2014;52(2):123-132.

3. Kumar R, Lim J, Mekary RA, et al. Traumatic spinal injury: global epidemiology and worldwide volume. World Neurosurg. 2018;113:e345-e363.

4. Rowland JW, Hawryluk GW, Kwon B, Fehlings MG. Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. Neurosurg Focus. 2008;25(5):E2.

5. Aarabi B, Hadley MN, Dhall SS, et al. Management of acute traumatic central cord syndrome (ATCCS). Neurosurgery. 2013;72 Suppl 2:195-204.

6. Ditunno JF, Little JW, Tessler A, Burns AS. Spinal shock revisited: a four-phase model. Spinal Cord. 2004;42(7):383-395.

7. Ryken TC, Hurlbert RJ, Hadley MN, et al. The acute cardiopulmonary management of patients with cervical spinal cord injuries. Neurosurgery. 2013;72 Suppl 2:84-92.

8. Lehmann KG, Lane JG, Piepmeier JM, Batsford WP. Cardiovascular abnormalities accompanying acute spinal cord injury in humans: incidence, time course and severity. J Am Coll Cardiol. 1987;10(1):46-52.

9. Jackson AB, Groomes TE. Incidence of respiratory complications following spinal cord injury. Arch Phys Med Rehabil. 1994;75(3):270-275.

10. Goldman JM, Rose LS, Williams SJ, Silver JR, Denison DM. Effect of abdominal binders on breathing in tetraplegic patients. Thorax. 1986;41(12):940-945.

11. Garshick E, Kelley A, Cohen SA, et al. A prospective assessment of mortality in chronic spinal cord injury. Spinal Cord. 2005;43(7):408-416.

12. Harrop JS, Sharan A, Ratliff J. Central cord injury: pathophysiology, management, and outcomes. Spine J. 2006;6(6 Suppl):198S-206S.

13. Waters RL, Adkins RH, Yakura JS, Sie I. Motor and sensory recovery following incomplete paraplegia. Arch Phys Med Rehabil. 1994;75(1):67-72.

14. Consortium for Spinal Cord Medicine. Prevention of venous thromboembolism in individuals with spinal cord injury: clinical practice guidelines for health care providers, 3rd edition. J Spinal Cord Med. 2016;39(3):361-383.

15. Sugimoto Y, Ito Y, Tomioka M, Kai N, Tanaka M. Deep venous thrombosis in patients with acute cervical spinal cord injury in a Japanese population: assessment with Doppler ultrasonography. J Orthop Sci. 2009;14(4):374-376.

16. Powell M, Kirshblum S, O'Connor KC. Duplex ultrasound screening for deep vein thrombosis in spinal cord injured patients at rehabilitation admission. Arch Phys Med Rehabil. 1999;80(9):1044-1046.

17. Gefen A. Risk factors for a pressure-related deep tissue injury: a theoretical model. Med Biol Eng Comput. 2007;45(6):563-573.

18. Cereda E, Gini A, Pedrolli C, Vanotti A. Disease-specific, versus standard, nutritional support for the treatment of pressure ulcers in institutionalized older adults: a randomized controlled trial. J Am Geriatr Soc. 2009;57(8):1395-1402.

19. Brindle CT, Wegelin JA. Prophylactic dressing application to reduce pressure ulcer incidence in critically ill patients. Adv Wound Care (New Rochelle). 2012;1(6):276-281.

20. Karlsson AK. Autonomic dysreflexia. Spinal Cord. 1999;37(6):383-391.

21. Cross LL, Meythaler JM, Tuel SM, Cross AL. Pregnancy, labor and delivery post spinal cord injury. Paraplegia. 1992;30(12):890-902.

22. Ayas S, Leblebici B, Sozay S, Bayramoglu M, Niron EA. The effect of abdominal massage on bowel function in patients with spinal cord injury. Am J Phys Med Rehabil. 2006;85(12):951-956.

23. Weld KJ, Dmochowski RR. Effect of bladder management on urological complications in spinal cord injured patients. J Urol. 2000;163(3):768-772.

24. Cardenas DD, Hoffman JM, Kirshblum S, McKinley W. Etiology and incidence of rehospitalization after traumatic spinal cord injury: a multicenter analysis. Arch Phys Med Rehabil. 2004;85(11):1757-1763.

25. Maynard FM, Karunas RS, Waring WP 3rd. Epidemiology of spasticity following traumatic spinal cord injury. Arch Phys Med Rehabil. 1990;71(8):566-569.

26. Watve SV, Sivan M, Raza WA, Jamil FF. The management of lower limb spasticity in patients with spinal cord damage. Br J Neurosurg. 2011;25(1):1-10.

27. Siddall PJ, McClelland JM, Rutkowski SB, Cousins MJ. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain. 2003;103(3):249-257.

28. Dalyan M, Cardenas DD, Gerard B. Upper extremity pain after spinal cord injury. Spinal Cord. 1999;37(3):191-195.

29. Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. JAMA. 1985;254(19):2792-2795.

30. Illman A, Stiller K, Williams M. The prevalence of orthostatic hypotension during physiotherapy treatment in patients with an acute spinal cord injury. Spinal Cord. 2000;38(12):741-747.

31. Cipriano CA, Pill SG, Keenan MA. Heterotopic ossification following traumatic brain injury and spinal cord injury. J Am Acad Orthop Surg. 2009;17(11):689-697.

32. Vanden Bossche L, Vanderstraeten G. Heterotopic ossification: a review. J Rehabil Med. 2005;37(3):129-136.

33. Buchholz AC, McGillivray CF, Pencharz PB. Differences in resting metabolic rate between paraplegic and able-bodied subjects are explained by differences in body composition. Am J Clin Nutr. 2003;77(2):371-378.

34. Xia X, Chen J, Xia J, et al. Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis. J Int Med Res. 2018;46(9):3596-3604.

35. Inouye SK, Bogardus ST Jr, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999;340(9):669-676.

36. Krassioukov AV, Karlsson AK, Wecht JM, et al. Assessment of autonomic dysfunction following spinal cord injury: rationale for additions to International Standards for Neurological Assessment. J Rehabil Res Dev. 2007;44(1):103-112.

37. Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet. 2009;373(9678):1874-1882.

38. Pang D, Pollack IF. Spinal cord injury without radiographic abnormality in children--the SCIWORA syndrome. J Trauma. 1989;29(5):654-664.

39. Miyanji F, Furlan JC, Aarabi B, Arnold PM, Fehlings MG. Acute cervical traumatic spinal cord injury: MR imaging findings correlated with neurologic outcome--prospective study with 100 consecutive patients. Radiology. 2007;243(3):820-827.

40. Kakulas BA. A review of the neuropathology of human spinal cord injury with emphasis on special features. J Spinal Cord Med. 1999;22(2):119-124.

41. Middleton JW, Lim K, Taylor L, Soden R, Rutkowski S. Patterns of morbidity and rehospitalisation following spinal cord injury. Spinal Cord. 2004;42(6):359-367.

42. Kirshblum SC, Burns SP, Biering-Sorensen F, et al. International standards for neurological classification of spinal cord injury (revised 2011). J Spinal Cord Med. 2011;34(6):535-546.

43. Fehlings MG, Vaccaro A, Wilson JR, et al. Early versus delayed decompression for traumatic cervical spinal cord injury: results of the Surgical Timing in Acute Spinal Cord Injury Study (STASCIS). PLoS One. 2012;7(2):e32037.

44. Stein DM, Sheth KN. Management of acute spinal cord injury. Continuum (Minneap Minn). 2015;21(1 Spinal Cord Disorders):159-187.

45. Bracken MB. Steroids for acute spinal cord injury. Cochrane Database Syst Rev. 2012;1:CD001046.

46. Cripps RA, Lee BB, Wing P, Weerts E, Mackay J, Brown D. A global map for traumatic spinal cord injury epidemiology: towards a living data repository for injury prevention. Spinal Cord. 2011;49(4):493-501.

47. Gorgey AS, Dolbow DR, Dolbow JD, Khalil RK, Castillo C, Gater DR. Effects of spinal cord injury on body composition and metabolic profile - part I. J Spinal Cord Med. 2014;37(6):693-702.

48. Goligher EC, Ferguson ND, Kenny LE. Core Curriculum in Critical Care: Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2017;196(9):1146-1160.

49. Bloemen-Vrencken JH, de Witte LP, Post MW, van den Heuvel WJ. Health behaviour of persons with spinal cord injury. Spinal Cord. 2007;45(3):243-249.

50. Rekand T, Hagen EM, Grønning M. Spasticity following spinal cord injury. Tidsskr Nor Laegeforen. 2012;132(8):970-973.

Additional Clinical Pearls for Advanced Practice

Pearl #15: The "Quad Cough Assist Technique"

When performing assisted cough for paraplegic patients with high thoracic injuries:

• Position hands below the xiphoid process
• Time thrust with patient's cough attempt
• Use firm, upward pressure (not downward/inward)
• Can increase peak expiratory flow by 40-60%
• Teach family members this technique before discharge

Pearl #16: The "Bladder Scanner Sweet Spot"

For accurate bladder volume measurements in SCI patients:

• Scan 2-3 cm superior to symphysis pubis
• Angle probe slightly caudally
• Perform in supine position when possible
• Values >500 mL warrant immediate catheterization
• Document volumes to establish patterns

Pearl #17: Early Signs of Autonomic Dysreflexia

Don't wait for the textbook presentation:

• Subtle early signs: Feeling "off," mild headache, anxiety
• Patient education: Teach patients to report ANY unusual sensation
• Proactive approach: Check BP with any new symptom in at-risk patients
• Early recognition prevents hypertensive crises

Pearl #18: The "Skin Moisture Paradox"

• Above injury level: May have excessive sweating (compensatory hyperhidrosis)
• Below injury level: Dry skin due to loss of sudomotor function
• Different moisturizing strategies needed for different body regions
• Excessive moisture above increases fungal infection risk
• Excessive dryness below increases pressure injury risk

Pearl #19: Sleep Architecture Disruption

SCI patients have significantly disrupted sleep:

• Increased sleep latency
• Reduced REM sleep
• Frequent awakenings
• Sleep apnea more common (even in paraplegia)
• Address sleep hygiene actively, not just with medications
• Consider sleep study if daytime somnolence persists

Pearl #20: The "Medication Absorption Challenge"

Altered GI motility affects medication pharmacokinetics:

• Delayed gastric emptying common
• Variable small bowel transit
• Extended-release formulations may not work predictably
• Consider liquid formulations when available
• Therapeutic drug monitoring more important

Advanced Hacks for Expert Practice

Hack #12: The "Pre-Procedure Autonomic Dysreflexia Protocol"

Create a standardized pre-procedure checklist for at-risk patients:

• 15 minutes before: Check baseline BP
• 10 minutes before: Apply topical anesthetic
• 5 minutes before: Position patient (sitting if possible)
• 0 minutes: Ensure nifedipine 10 mg at bedside
• During: Monitor BP every 2-3 minutes
• Post: Monitor for 30 minutes

Hack #13: The "Bowel Program Time Optimization"

Work backwards from desired evacuation time:

• Target evacuation time: 8:00 AM
• Stimulant administration: 7:30 AM (30 min prior)
• Warm fluid intake: 7:00 AM (stimulates gastrocolic reflex)
• Positioning: 7:45 AM (upright if possible)
• This schedule synchronizes physiological triggers

Hack #14: The "Spasticity Diary"

Have patients/nurses keep a simple log:

• Time of spasm
• Severity (1-10)
• Trigger (if identified)
• Duration
• Response to interventions Patterns emerge within 3-5 days that guide targeted therapy

Hack #15: The "Transfer Safety Triad"

Before any transfer, check three things:

1. Lock status: All wheels locked, bed brakes engaged
2. Positioning: Transfer surface at appropriate height
3. Pathway clear: Remove obstacles, ensure adequate space This 5-second check prevents 90% of transfer injuries

Hack #16: The "Pressure Mapping Protocol"

For patients with recurrent pressure injuries:

• Use pressure mapping when available
• Map in multiple positions (supine, sitting, lateral)
• Identify "hot spots" (>32 mmHg sustained)
• Customize cushioning based on data
• Recheck after position/equipment changes

Hack #17: The "Pain Pattern Recognition"

Different pain patterns suggest different interventions:

• Burning/electric: Neuropathic → gabapentinoids
• Aching/tight: Musculoskeletal → NSAIDs, physical therapy
• Sharp/shooting: Radicular → consider imaging
• Visceral/deep: Check bowel/bladder, rule out pathology Match medication to mechanism

Hack #18: The "Antibiotic Stewardship in SCI"

Urinalysis interpretation differs in SCI:

• Asymptomatic bacteriuria is nearly universal
• Pyuria without symptoms does NOT require treatment
• Treat only symptomatic UTIs:
  • Fever
  • Increased spasticity
  • Autonomic dysreflexia
  • Cloudy/malodorous urine WITH symptoms
  • Change in character of incontinence

This approach reduces antibiotic resistance significantly

Hack #19: The "Family Education Touchpoints"

Schedule specific education sessions:

• Day 1-2: Diagnosis, prognosis, expectations
• Day 3-5: Complications to watch for, emergency management
• Week 2: Transfer techniques, basic care
• Week 3-4: Bowel/bladder programs, skin care
• Pre-discharge: Equipment, home modifications, emergency plans Scheduled approach ensures nothing is missed

Hack #20: The "Discharge Readiness Checklist"

Patient/family must demonstrate competence in:

• [ ] Pressure relief techniques
• [ ] Skin inspection with mirrors
• [ ] Bladder management (catheterization if applicable)
• [ ] Bowel program execution
• [ ] Transfer techniques
• [ ] Recognition of AD and initial management
• [ ] Recognition of DVT symptoms
• [ ] Equipment troubleshooting
• [ ] Emergency contact information
• [ ] Follow-up appointments scheduled

Don't discharge until ALL boxes checked

Oyster Pearls (Rare but Important)

Oyster #9: Post-Traumatic Syringomyelia

Develops in 3-8% of SCI patients months to years after injury:

• Presents with ascending sensory loss, pain, increased spasticity
• Can occur even years after "stable" injury
• Requires MRI for diagnosis
• May need neurosurgical intervention (syrinx drainage/shunting)
• Key: Any change in neurological status warrants imaging

Oyster #10: The "Quad Cough" Variant for Paraplegics

Even paraplegics with normal upper extremities can benefit from modified assisted cough:

• Self-assisted technique using arms to compress abdomen
• "Huff cough" technique (forced expiration with open glottis)
• Can improve secretion clearance by 25-30%
• Teach during acute phase for long-term use

Oyster #11: Sexual Function and Fertility

Often overlooked in acute care but important to address:

• Males:

  • Reflex erections possible with upper motor neuron lesions
  • Fertility reduced but possible
  • Phosphodiesterase inhibitors often effective
  • Refer to urology early

• Females:

  • Menses typically return within 6 months
  • Fertility generally preserved
  • Pregnancy possible and increasingly common
  • High-risk obstetric referral essential

Brief mention plants seed for later comprehensive discussion

Oyster #12: The "Aspiration Risk Paradox"

Paraplegic patients may have INCREASED aspiration risk despite no direct respiratory muscle involvement:

• Gastroesophageal reflux more common (delayed gastric emptying)
• Impaired cough effectiveness
• Medications (anticholinergics, opioids) worsen dysmotility
• Consider swallow evaluation if any respiratory symptoms

Oyster #13: Ossification of Ligamentum Flavum

Rare complication in chronic SCI:

• Progressive ligamentous ossification
• Can cause spinal stenosis
• Presents with gradual neurological deterioration
• More common in Asian populations
• CT better than MRI for detection

Oyster #14: Chronic Pain Evolution

Pain character changes over time:

• Acute phase: Nociceptive predominates
• Subacute (weeks-months): Mixed picture
• Chronic (>6 months): Central neuropathic pain develops
• Treatment strategies must evolve accordingly
• Early aggressive management may prevent chronic pain syndrome

Oyster #15: The "Hidden" Fractures

In paraplegic patients, occult fractures are common:

• No pain signal to alert patient
• First sign may be swelling, warmth, or increased spasticity
• Lower extremity fractures from minor trauma (transfers, spasms)
• Low threshold for imaging with any unexplained limb changes
• These fractures can trigger severe AD episodes

Oyster #16: Renal Complications (Long-term Awareness)

While not immediately relevant in ICU, worth mentioning:

• Chronic kidney disease develops in 10-15% over decades
• Risk factors: recurrent UTIs, nephrolithiasis, bladder management method
• Annual renal function monitoring essential
• Early nephrology referral for any decline

Oyster #17: The "Incomplete Incomplete" Injury

Some patients have preserved sensation but no motor function (or vice versa):

• Complete motor, incomplete sensory: Can be psychologically devastating (feel everything but can't move)
• Incomplete motor, complete sensory: Risk of injury from inability to detect problems
• Require individualized rehabilitation approaches
• Psychological support crucial for both patterns

Oyster #18: Cardiac Remodeling in Chronic SCI

Over time, cardiovascular changes occur:

• Left ventricular atrophy (reduced demand)
• Reduced stroke volume
• Chronically lower blood pressures become "normal"
• "Normal" BP for general population may represent hypertension in chronic SCI
• Important for long-term cardiac risk assessment

Oyster #19: The "Brown-Séquard Plus" Syndrome

Pure hemisection is rare; most have features of Brown-Séquard plus additional findings:

• Ipsilateral motor loss
• Ipsilateral proprioception loss
• Contralateral pain/temperature loss
• Plus: Variable central cord syndrome features
• Better prognosis than complete injuries
• Up to 90% achieve ambulatory function

Oyster #20: Respiratory Muscle Fatigue Window

A dangerous period exists 2-4 weeks post-injury:

• Initial sympathetic surge subsides
• Respiratory muscles begin to fatigue
• Before strengthening adaptations occur
• Heightened vigilance for respiratory failure needed
• May need temporary ventilatory support even if initially stable

Multidisciplinary Team Considerations

The SCI Critical Care Team Should Include:

Core Team:

• Intensivist
• Neurosurgeon/Orthopedic spine surgeon
• Nurse specialist (dedicated SCI if possible)
• Physical therapist
• Occupational therapist
• Respiratory therapist

Essential Consultants:

• Physiatrist (PM&R)
• Psychology/Psychiatry
• Social work/Case management
• Nutrition
• Urology
• Wound care specialist

Important but Often Overlooked:

• Biomedical engineering (for equipment needs)
• Recreational therapy
• Spiritual care
• Peer support (individuals with SCI)
• Vocational counselor (early involvement better)

Communication Strategies:

Hack #21: The "24-Hour Look-Ahead Board" Create visible board with next 24 hours' plan:

• Procedures scheduled
• Mobility goals
• Family meetings
• New interventions to trial
• Potential discharge barriers

Entire team knows the plan, reduces redundant questions to patient/family

Telemedicine and Remote Monitoring Considerations

Increasingly relevant for SCI follow-up:

• Teledermatology for pressure injury monitoring
• Remote vital sign monitoring
• Video consultations for routine follow-up
• Digital bladder/bowel diaries
• Remote spasticity assessment tools

Pearl #21: Establish telemedicine follow-up BEFORE discharge. First virtual visit should be within 1 week of discharge when most problems manifest.

Quality Improvement Initiatives

Measurable QI Projects for SCI Care:

1. Pressure Injury Prevention Bundle:

   • Reduce hospital-acquired pressure injuries to zero
   • Track compliance with repositioning protocols
   • Measure surface adequacy assessments

2. VTE Prophylaxis Compliance:

   • Achieve >95% prophylaxis within 72 hours
   • Zero missed doses
   • Standardized surveillance protocol

3. Early Mobilization Program:

   • Track time to first mobilization
   • Measure mobility minutes per day
   • Assess barriers to mobilization

4. Family Satisfaction:

   • Regular surveys
   • Communication effectiveness metrics
   • Educational material comprehension assessment

5. Delirium Reduction:

   • CAM-ICU compliance
   • Sleep protocol implementation
   • Psychoactive medication reduction

Hack #22: Create a "SCI Dashboard" Single-page visual display showing:

• Days since last pressure injury
• Current VTE prophylaxis compliance
• Average time to mobilization
• Family satisfaction scores
• Length of stay trends

Display prominently in unit; creates accountability and celebrates successes

Conclusion and Future Directions

The landscape of spinal cord injury care continues to evolve rapidly. While we await breakthrough regenerative therapies, the foundation of excellent SCI critical care remains:

1. Meticulous attention to detail in preventing secondary complications
2. Aggressive early intervention to optimize neurological recovery
3. Multidisciplinary collaboration leveraging diverse expertise
4. Patient and family engagement as true partners in care
5. Continuous quality improvement to enhance outcomes

The pearls, oysters, and hacks presented in this review represent the accumulated wisdom of decades of SCI care. They are the small details that collectively make enormous differences in outcomes. Master the fundamentals, embrace the nuances, and never underestimate the impact of thoughtful, comprehensive care.

As critical care physicians, we have the privilege and responsibility of caring for paraplegic patients during their most vulnerable time. The care we provide—or fail to provide—in the ICU reverberates throughout their lifetime. Every pressure injury prevented, every respiratory complication avoided, and every moment of dignity preserved contributes to not just survival, but to a life worth living after SCI.

The future holds promise: epidural stimulation restoring movement, advanced neuroprotective agents, refined surgical techniques, and perhaps one day, true regeneration. Until then, we must perfect the art and science of what we can do now. Excellence in SCI critical care is not a single intervention but rather the seamless integration of hundreds of evidence-based practices, clinical insights, and compassionate human connection.

Let this review serve as both a comprehensive guide and a call to action—to elevate the standard of care for every paraplegic patient who enters our ICUs, to prevent the preventable, to optimize the recoverable, and to support the irreplaceable human being behind every injury.

---

Author's Note for Medical Educators:

This review has been crafted with the specific needs of postgraduate medical education in mind. The integration of "pearls" (practical clinical insights), "oysters" (rare but important knowledge), and "hacks" (efficient workflows and mnemonics) is designed to enhance retention and clinical application. When presenting this material:

• Use case-based discussions to illustrate key points
• Encourage learners to develop their own institutional protocols based on these principles
• Emphasize that SCI care is a marathon, not a sprint—sustained attention over weeks matters
• Foster multidisciplinary thinking from day one
• Remember that behind every "case" is a person whose life has been irrevocably changed

The goal is not just to create competent physicians, but compassionate caregivers who understand that SCI care excellence lies in the details.

The Immunology of Cancer: A Primer on Immunotherapy

 

The Immunology of Cancer: A Primer on Immunotherapy for the Internist

Dr Neeraj Manikath , claude.ai

Abstract

Cancer immunotherapy has revolutionized oncological care over the past decade, transforming previously untreatable malignancies into manageable chronic diseases. As immunotherapy becomes increasingly prevalent, internists and critical care physicians encounter patients with immune-related complications that demand prompt recognition and management. This comprehensive review elucidates the mechanisms underlying modern immunotherapeutic approaches, details the spectrum of immune-related adverse events (irAEs), and provides practical guidance for managing these complex patients. We discuss immune checkpoint inhibitors, CAR-T cell therapy, the paradox of hyperprogressive disease, and predictive biomarkers—equipping the intensivist with essential knowledge to optimize outcomes in this evolving therapeutic landscape.

Keywords: Cancer immunotherapy, immune checkpoint inhibitors, CAR-T cells, cytokine release syndrome, immune-related adverse events, PD-1, PD-L1, CTLA-4

---

Introduction

The concept of harnessing the immune system to combat cancer dates back over a century to William Coley's bacterial toxin experiments. However, only in recent decades has our understanding of tumor immunology matured sufficiently to develop effective immunotherapies. The 2018 Nobel Prize in Physiology or Medicine, awarded to James Allison and Tasuku Honjo for their work on CTLA-4 and PD-1 respectively, underscored the paradigm shift in cancer treatment.

Unlike conventional cytotoxic chemotherapy that directly targets malignant cells, immunotherapy reactivates and augments the patient's own immune system to recognize and eliminate cancer. This fundamental difference in mechanism accounts for both the remarkable durability of responses—some lasting years beyond treatment cessation—and the unique toxicity profile characterized by immune-related adverse events (irAEs).

For the internist and intensivist, understanding cancer immunology is no longer optional. Patients receiving immunotherapy may present acutely with life-threatening complications such as fulminant colitis, severe pneumonitis, or cytokine release syndrome. Recognition of these syndromes and prompt intervention can be lifesaving. This review provides a comprehensive yet practical guide to the immunology of cancer and its therapeutic implications.

---

Immune Checkpoint Inhibitors (ICI): How Anti-PD-1/PD-L1 and Anti-CTLA-4 Drugs Work

The Cancer-Immunity Cycle and Immune Evasion

To understand checkpoint inhibitors, one must first appreciate the cancer-immunity cycle. This process involves tumor antigen release, antigen presentation by dendritic cells, T-cell priming and activation, trafficking to the tumor microenvironment, tumor infiltration, and cancer cell recognition and killing. At each stage, regulatory mechanisms exist to prevent excessive immune activation and autoimmunity.

Cancer cells exploit these regulatory checkpoints to evade immune surveillance—a phenomenon termed "immune escape." The two most clinically relevant checkpoints are CTLA-4 (Cytotoxic T-Lymphocyte Antigen-4) and the PD-1/PD-L1 (Programmed Death-1/Programmed Death Ligand-1) axis.

CTLA-4: The Brake on T-Cell Priming

CTLA-4 functions primarily in lymphoid organs during the initial phase of T-cell activation. When naive T cells encounter antigen-presenting cells (APCs), they require two signals: TCR engagement with MHC-peptide complexes (Signal 1) and costimulation via CD28-B7 interaction (Signal 2). CTLA-4, constitutively expressed on regulatory T cells (Tregs) and upregulated on activated effector T cells, competes with CD28 for B7 binding but delivers an inhibitory signal instead.

CTLA-4 has approximately 20-fold higher affinity for B7 molecules than CD28, effectively outcompeting the activating signal. Additionally, CTLA-4 can trans-endocytose B7 molecules from APCs, depleting them from the cell surface and further dampening T-cell activation.

Ipilimumab (Yervoy), the first FDA-approved checkpoint inhibitor (2011), blocks CTLA-4. By preventing CTLA-4 engagement, ipilimumab amplifies T-cell priming and promotes anti-tumor immunity. However, this mechanism is relatively non-specific, affecting both tumor-reactive and self-reactive T cells, which explains the higher incidence of irAEs with anti-CTLA-4 therapy compared to PD-1 inhibitors.

PD-1/PD-L1: The Peripheral Checkpoint

The PD-1/PD-L1 axis operates primarily in peripheral tissues, including the tumor microenvironment, functioning as an "off switch" for T cells that have already been activated and have infiltrated tissues. PD-1 is expressed on activated T cells, B cells, and natural killer cells. Its ligands, PD-L1 (B7-H1) and PD-L2, are expressed on various cell types including tumor cells, immune cells, and stromal cells.

When PD-1 binds to PD-L1 or PD-L2, it recruits phosphatases (SHP-1 and SHP-2) that dephosphorylate key signaling molecules downstream of the T-cell receptor, effectively inhibiting T-cell activation, proliferation, and cytokine production. Many tumors upregulate PD-L1 expression as an adaptive immune resistance mechanism—a process often driven by interferon-gamma (IFN-γ) secreted by tumor-infiltrating lymphocytes.

Anti-PD-1 antibodies include:

• Pembrolizumab (Keytruda) - approved 2014
• Nivolumab (Opdivo) - approved 2014
• Cemiplimab (Libtayo) - approved 2018

Anti-PD-L1 antibodies include:

• Atezolizumab (Tecentriq) - approved 2016
• Durvalumab (Imfinzi) - approved 2017
• Avelumab (Bavencio) - approved 2017

Blocking this interaction reinvigorates exhausted T cells within the tumor microenvironment, restoring their ability to recognize and kill cancer cells. The more targeted peripheral mechanism of PD-1/PD-L1 blockade generally results in a lower incidence of severe irAEs compared to CTLA-4 inhibition.

Combination Therapy: Synergistic but Toxic

The CheckMate 067 trial demonstrated that combining ipilimumab with nivolumab in metastatic melanoma significantly improved overall survival compared to either agent alone (median OS: 72.1 months vs 36.9 months for nivolumab and 19.9 months for ipilimumab). However, grade 3-4 irAEs occurred in 59% of combination patients versus 21% with nivolumab alone.

This synergy reflects the complementary mechanisms: CTLA-4 blockade enhances initial T-cell activation in lymph nodes, while PD-1 blockade sustains T-cell function in the tumor microenvironment. The combination effectively removes both central and peripheral brakes on anti-tumor immunity.

Clinical Pearl: Not All Responses Are Rapid

Unlike chemotherapy, where response is typically assessed within 6-8 weeks, immunotherapy responses may be delayed. Pseudoprogression—initial radiographic tumor enlargement followed by subsequent shrinkage—occurs in 5-10% of patients due to immune cell infiltration. The iRECIST criteria were developed to account for these unique response patterns. Clinicians must resist premature discontinuation in clinically stable patients with apparent radiographic progression.

Oyster: Duration of Therapy Remains Uncertain

Most trials limited checkpoint inhibitor therapy to 2 years, yet the optimal duration remains undefined. Some patients maintain durable responses after discontinuation, while others relapse. The KEYNOTE-024 trial showed that pembrolizumab for 2 years in NSCLC resulted in 5-year survival of 32% versus 16% with chemotherapy. Retreatment after progression can be effective, but rechallenge increases irAE risk.

---

Managing Immune-Related Adverse Events (irAEs): Colitis, Pneumonitis, Dermatitis, and Endocrinopathies

General Principles of irAE Management

Immune-related adverse events represent on-target, off-tumor toxicity—the immune system attacking normal tissues. Unlike traditional chemotherapy toxicities that are dose-dependent and predictable, irAEs can affect virtually any organ system, occur at any time (even months after treatment cessation), and vary widely in severity.

The cornerstone of irAE management rests on three principles:

1. Early recognition and grading using the Common Terminology Criteria for Adverse Events (CTCAE)
2. Prompt immunosuppression with corticosteroids as first-line therapy
3. Multidisciplinary collaboration with oncology, gastroenterology, pulmonology, endocrinology, and rheumatology

Immune-Related Colitis

Gastrointestinal irAEs are among the most common, particularly with anti-CTLA-4 therapy. Immune-related colitis occurs in 8-27% of patients receiving ipilimumab and 1-3% with PD-1 inhibitors. Combination therapy increases risk to 10-13%.

Clinical Presentation:

• Diarrhea (>6 stools/day above baseline)
• Abdominal pain and cramping
• Hematochezia or melena
• Fever (in severe cases)
• Symptoms typically develop 6-8 weeks after initiation but can occur throughout treatment

Diagnostic Approach:

• Stool studies: C. difficile, ova and parasites, culture, fecal calprotectin (usually elevated >250 μg/g)
• Laboratory tests: CBC, CMP, CRP, albumin
• CT abdomen/pelvis: colonic wall thickening, pericolonic fat stranding
• Colonoscopy with biopsies: required for grade 2 or higher; reveals diffuse colitis with histologic patterns similar to inflammatory bowel disease

Grading and Management:

Grade 1 (Increase of <4 stools/day):

• Continue immunotherapy with monitoring
• Symptomatic treatment: loperamide, hydration
• Dietary modification: low-residue diet

Grade 2 (4-6 stools/day, moderate abdominal pain):

• Hold immunotherapy
• Prednisone 0.5-1 mg/kg/day PO
• If no improvement in 3-5 days, escalate to Grade 3 management
• Resume immunotherapy after symptoms resolve to grade 1 and steroids tapered to ≤10 mg/day

Grade 3 (≥7 stools/day, severe abdominal pain, peritoneal signs):

• Permanently discontinue immunotherapy
• Hospitalize for close monitoring
• Methylprednisolone 1-2 mg/kg/day IV
• If refractory to steroids after 3-5 days, add:
  • Infliximab 5 mg/kg IV (avoid if perforation suspected)
  • OR vedolizumab 300 mg IV (gut-selective, preferred if infection concern)
• Colonoscopy to assess severity and rule out CMV colitis
• Surgical consultation for signs of perforation

Grade 4 (Life-threatening, perforation, toxic megacolon):

• ICU admission
• High-dose methylprednisolone 2 mg/kg/day IV
• Infliximab 5 mg/kg IV
• Immediate surgical consultation
• Broad-spectrum antibiotics if perforation suspected

Clinical Hack: The "Infliximab vs Vedolizumab" Decision

While infliximab is the traditional second-line agent, vedolizumab offers gut-specific immunosuppression with potentially lower infection risk. In patients with suspected concurrent infection or those who are severely immunocompromised, vedolizumab may be preferable. The AVOID trial is currently comparing these agents head-to-head.

Pearl: CMV Reactivation

Corticosteroid-refractory colitis should prompt CMV testing via immunohistochemistry on colonic biopsies or serum CMV PCR. CMV reactivation occurs in up to 20% of steroid-refractory cases. Treatment requires ganciclovir or foscarnet in addition to immunosuppression tapering.

Immune-Related Pneumonitis

Pneumonitis represents one of the most serious irAEs, with mortality rates of 10-17% in severe cases. Incidence is 3-5% with PD-1/PD-L1 inhibitors and <1% with CTLA-4 inhibitors. Combination therapy increases risk to 7-10%. Pneumonitis typically develops 2-6 months after initiation but can occur at any time.

Clinical Presentation:

• Dyspnea (most common)
• Non-productive cough
• Fever (variably present)
• Hypoxemia
• Often insidious onset, easily mistaken for disease progression or infection

Radiographic Patterns:

• Cryptogenic organizing pneumonia (COP): patchy consolidations
• Non-specific interstitial pneumonia (NSIP): ground-glass opacities
• Hypersensitivity pneumonitis: ground-glass and centrilobular nodules
• Acute interstitial pneumonia/ARDS: diffuse alveolar damage

Diagnostic Workup:

• Chest CT (high-resolution if available): essential for diagnosis
• Oxygen saturation and ABG
• Infectious workup: sputum cultures, respiratory viral panel, blood cultures
• Consider bronchoscopy with BAL if diagnosis uncertain:
  • Lymphocytic predominance (typically CD4+ or CD8+)
  • Rule out infection, malignancy, hemorrhage
  • Transbronchial biopsy rarely necessary

Grading and Management:

Grade 1 (Asymptomatic, radiographic only):

• Hold immunotherapy
• Close monitoring with weekly assessment
• Repeat imaging in 3-4 weeks
• If resolved, consider rechallenge with careful surveillance

Grade 2 (Symptomatic, not limiting ADLs):

• Hold immunotherapy
• Prednisone 1 mg/kg/day PO (or IV equivalent)
• Broad empiric antibiotics until infection excluded
• Hospitalize if borderline or high clinical suspicion for rapid deterioration
• Improvement expected in 48-72 hours; if not, treat as Grade 3

Grade 3 (Severe symptoms, limiting ADLs, oxygen required):

• Permanently discontinue immunotherapy
• Hospitalize (ICU if hypoxemic despite supplemental oxygen)
• Methylprednisolone 2-4 mg/kg/day IV divided q6-8h
• Broad-spectrum antibiotics until infection definitively ruled out
• Bronchoscopy strongly recommended
• If no improvement in 48-72 hours, add:
  • Infliximab 5 mg/kg IV, OR
  • Mycophenolate mofetil 1000 mg PO BID, OR
  • Cyclophosphamide 500-1000 mg/m² IV, OR
  • IVIG 2 g/kg divided over 2-5 days

Grade 4 (Life-threatening, mechanical ventilation):

• ICU admission with mechanical ventilation
• High-dose methylprednisolone 1000 mg IV daily x 3 days, then 2-4 mg/kg/day
• Early addition of second immunosuppressant (infliximab, mycophenolate, or IVIG)
• Lung-protective ventilation strategies
• Consider plasmapheresis in refractory cases (limited evidence)

Steroid Taper: Pneumonitis requires prolonged immunosuppression. After clinical and radiographic improvement, taper steroids slowly over 4-8 weeks (or longer). Rapid tapers frequently result in rebound inflammation. Maintain at least 10-20 mg prednisone daily for minimum 4 weeks before further reduction.

Oyster: Sarcoid-Like Reactions

A subset of patients develops sarcoid-like granulomatous inflammation with hilar lymphadenopathy, which can be mistaken for disease progression. Unlike typical pneumonitis, sarcoid reactions may not require treatment if asymptomatic. PET avidity in lymph nodes may persist despite clinical response.

Clinical Hack: The "Steroid Response Test"

If diagnostic uncertainty exists between pneumonitis and disease progression, a trial of high-dose steroids (1-2 mg/kg/day) for 48-72 hours can be diagnostic. Pneumonitis typically shows rapid clinical improvement, while progression does not respond. However, this approach should not delay bronchoscopy in appropriate candidates.

Immune-Related Dermatitis

Cutaneous irAEs are the most common toxicity, occurring in 30-40% of patients, though usually mild. Severe reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) are rare (<1%) but life-threatening.

Common Presentations:

Maculopapular Rash (most common):

• Erythematous, pruritic rash
• Trunk and extremities
• Usually develops within 3-6 weeks
• Grade 1-2: topical corticosteroids and antihistamines
• Grade 3: systemic corticosteroids 0.5-1 mg/kg/day

Pruritus without Rash:

• Can be severe and debilitating
• Treatment: antihistamines (hydroxyzine, cetirizine), menthol creams
• Consider systemic steroids if refractory
• Aprepitant 80 mg daily (off-label) may help refractory cases

Vitiligo:

• Occurs in 3-5% of melanoma patients
• Paradoxically associated with better outcomes
• No treatment required; cosmetically bothersome to some patients

Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN):

• Medical emergency
• Mucosal involvement, skin detachment >10% BSA (TEN)
• Permanently discontinue immunotherapy
• High-dose IV methylprednisolone 1-2 mg/kg/day
• Consider IVIG 2-3 g/kg over 3-5 days
• Burn unit consultation
• Supportive care: fluid resuscitation, wound care, infection prevention

Pearl: Lichenoid Reactions

Oral lichenoid reactions can mimic oral lichen planus with painful oral ulcerations. Unlike typical drug reactions, these may persist for months. Treatment includes topical clobetasol, dexamethasone oral rinses, and systemic steroids for severe cases.

Immune-Related Endocrinopathies

Endocrine irAEs are common (10-15% with PD-1 inhibitors) and often permanent, requiring lifelong hormone replacement. Unlike other irAEs, they rarely respond to immunosuppression once established.

Hypothyroidism:

• Most common endocrinopathy (6-10%)
• Often preceded by transient thyroiditis with hyperthyroidism
• Symptoms: fatigue, weight gain, cold intolerance, constipation
• Diagnosis: elevated TSH, low free T4
• Treatment: levothyroxine replacement (start 25-50 mcg daily, titrate)
• Immunotherapy may continue with thyroid replacement

Hyperthyroidism/Thyroiditis:

• Transient thyrotoxicosis (2-4% of patients)
• Symptoms: tachycardia, tremor, weight loss, anxiety
• Labs: suppressed TSH, elevated T3/T4
• Treatment: beta-blockers (propranolol 10-40 mg TID), symptom management
• Typically resolves in 4-8 weeks, often followed by hypothyroidism
• Anti-thyroid drugs (methimazole) generally NOT helpful

Hypophysitis:

• More common with CTLA-4 inhibitors (8-10% with ipilimumab vs 1% with PD-1)
• Symptoms: headache, fatigue, visual changes, nausea
• MRI: pituitary enlargement, stalk thickening (though may be normal)
• Diagnosis: low morning cortisol (<5 μg/dL), low ACTH, variable TSH/T4
• Test for adrenal insufficiency immediately
• Treatment:
  • Hydrocortisone 15-25 mg daily in divided doses (stress dosing if acute)
  • Levothyroxine if secondary hypothyroidism (only AFTER cortisol replacement)
  • High-dose steroids (prednisone 1 mg/kg) may preserve pituitary function if caught early
• Immunotherapy may continue with hormone replacement

Type 1 Diabetes Mellitus:

• Rare (<1%) but abrupt onset with DKA
• More common with PD-1 inhibitors
• Diagnosis: hyperglycemia, ketones, low/absent C-peptide, positive GAD/IA-2 antibodies
• Treatment: insulin therapy, standard DKA management
• Permanent; requires lifelong insulin

Primary Adrenal Insufficiency:

• Rare; can be life-threatening
• Symptoms: fatigue, nausea, hypotension, hyponatremia, hyperkalemia
• Diagnosis: low cortisol, elevated ACTH (distinguishes from hypophysitis)
• Treatment: hydrocortisone replacement, fludrocortisone
• Adrenal crisis requires immediate hydrocortisone 100 mg IV

Clinical Hack: Screen Early, Screen Often

Obtain baseline TSH, free T4, and morning cortisol before starting immunotherapy. Repeat TSH every 6-12 weeks during treatment. For patients with vague symptoms (fatigue, headache), check cortisol FIRST before assuming progression or other causes. A low morning cortisol (<10 μg/dL) warrants endocrinology consultation; <5 μg/dL is diagnostic of insufficiency.

Oyster: The ACTH Conundrum

In secondary adrenal insufficiency from hypophysitis, ACTH may be low, normal, or even mildly elevated despite inadequate cortisol stimulation. Do not rely on ACTH alone—if morning cortisol is <10 μg/dL in a symptomatic patient, perform a cosyntropin stimulation test or empirically treat.

Other Notable irAEs

Myocarditis:

• Rare (1-2%) but highest case fatality rate (25-50%)
• Presents with dyspnea, chest pain, arrhythmias, heart failure
• Troponin elevation (often dramatic), ECG changes, reduced ejection fraction
• Diagnosis: cardiac MRI (edema, late gadolinium enhancement), endomyocardial biopsy
• Treatment:
  • Permanently discontinue immunotherapy
  • High-dose methylprednisolone 1000 mg IV daily x 3-5 days
  • Infliximab if refractory (caution with heart failure)
  • Mycophenolate or abatacept may be added
  • IVIG in severe cases
  • Standard heart failure management
  • Temporary pacing if high-grade AV block

Neurological irAEs:

• Diverse presentations: peripheral neuropathy, myasthenia gravis, Guillain-Barré syndrome, encephalitis, aseptic meningitis
• Often severe and refractory to treatment
• Workup: MRI brain/spine, LP, nerve conduction studies, acetylcholine receptor antibodies
• Treatment: high-dose steroids, IVIG, plasmapheresis
• Neurology consultation essential

Nephritis:

• Usually asymptomatic; detected by creatinine elevation
• Acute interstitial nephritis most common
• Diagnosis: urinalysis (proteinuria, hematuria, sterile pyuria), kidney biopsy if diagnosis uncertain
• Treatment: hold immunotherapy, prednisone 0.5-1 mg/kg/day

---

CAR-T Cell Therapy: Mechanism and the Dangers of Cytokine Release Syndrome (CRS)

CAR-T Cell Therapy: Engineering Immunity

Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a paradigm shift in cancer treatment—a "living drug" that replicates and persists within the patient. Unlike checkpoint inhibitors that release existing brakes on immunity, CAR-T therapy involves ex vivo genetic modification of autologous T cells to recognize tumor-specific antigens.

The CAR Structure:

A typical CAR consists of four components:

1. Extracellular antigen-recognition domain: Usually derived from a monoclonal antibody's single-chain variable fragment (scFv), recognizes tumor surface antigens (e.g., CD19, BCMA)
2. Hinge/spacer region: Provides flexibility and optimal target engagement
3. Transmembrane domain: Anchors the CAR to T-cell surface
4. Intracellular signaling domains:
   • CD3ζ chain (Signal 1): activates T cell
   • Costimulatory domains (Signal 2): CD28 and/or 4-1BB enhance T-cell proliferation, cytokine production, and persistence

FDA-Approved CAR-T Products:

CD19-Targeted (B-cell malignancies):

• Tisagenlecleucel (Kymriah): ALL, DLBCL
• Axicabtagene ciloleucel (Yescarta): DLBCL, follicular lymphoma, mantle cell lymphoma
• Brexucabtagene autoleucel (Tecartus): mantle cell lymphoma, ALL
• Lisocabtagene maraleucel (Breyanzi): DLBCL

BCMA-Targeted (Multiple Myeloma):

• Idecabtagene vicleucel (Abecma)
• Ciltacabtagene autoleucel (Carvykti)

The CAR-T Process:

1. Leukapheresis: T cells collected from patient
2. Manufacturing: T cells genetically modified (viral transduction or CRISPR-based methods) to express CAR
3. Expansion: Modified T cells cultured and expanded (typically 2-4 weeks)
4. Lymphodepleting chemotherapy: Fludarabine and cyclophosphamide given days -5 to -3 to "make space" for CAR-T cells and enhance their expansion
5. CAR-T infusion: Single infusion of CAR-T cells (day 0)
6. Monitoring: Close observation for CRS and neurotoxicity, typically weeks 1-4 post-infusion

Cytokine Release Syndrome (CRS)

CRS is the most common serious toxicity of CAR-T therapy, occurring in 50-90% of patients (severe in 10-30%). It results from massive immune activation and cytokine release following CAR-T cell engagement with tumor cells.

Pathophysiology:

CAR-T cells recognize and engage target antigen → T-cell activation and proliferation → release of inflammatory cytokines (IL-6, IL-1, IL-2, IL-8, IFN-γ, TNF-α) → activation of monocytes/macrophages and endothelial cells → amplification cascade → systemic inflammatory response syndrome (SIRS).

IL-6 is the key driver of CRS severity. Elevated IL-6 correlates with fever, hypotension, and organ dysfunction. Importantly, CRS is mediated primarily by monocytes/macrophages (responding to CAR-T cytokines) rather than CAR-T cells themselves.

Clinical Presentation:

Onset: Typically 1-14 days post-infusion (median 3-5 days). Earlier onset often correlates with higher tumor burden and more severe CRS.

Symptoms/Signs:

• Fever (defining feature, often high-grade)
• Tachycardia, hypotension (may progress to shock requiring vasopressors)
• Hypoxia (capillary leak, ARDS)
• End-organ dysfunction: acute kidney injury, transaminitis, coagulopathy (elevated D-dimer, hypofibrinogenemia)
• Constitutional symptoms: fatigue, myalgias, nausea

Grading CRS (ASTCT Consensus Grading 2019):

Grade 1:

• Fever ≥38°C
• No hypotension, no hypoxia requiring intervention

Grade 2:

• Fever ≥38°C
• Hypotension responsive to fluids OR
• Hypoxia requiring low-flow oxygen (≤6 L/min or FiO₂ <40%)

Grade 3:

• Fever ≥38°C
• Hypotension requiring vasopressor (with or without vasopressin) OR
• Hypoxia requiring high-flow oxygen (>6 L/min or FiO₂ ≥40%)

Grade 4:

• Fever ≥38°C
• Hypotension requiring multiple vasopressors (excluding vasopressin) OR
• Hypoxia requiring positive pressure ventilation

Laboratory Findings:

• Elevated CRP (often >20 mg/dL), ferritin (>10,000 ng/mL in severe cases)
• IL-6 levels elevated (correlate with severity)
• Elevated D-dimer, prolonged PT/PTT
• Transaminitis, hyperbilirubinemia
• Acute kidney injury (elevated creatinine)
• Cytopenias (especially if bone marrow involvement)

Management of CRS:

Supportive Care (All Grades):

• Aggressive IV hydration (caution in severe CRS with capillary leak)
• Antipyretics: acetaminophen (avoid NSAIDs due to renal concerns)
• Broad-spectrum antibiotics if infection suspected (fever may mask sepsis)
• Monitor vital signs frequently; ICU transfer threshold should be low

Grade 1:

• Observation, supportive care
• Hold CAR-T-related prophylactic antimicrobials if possible
• Monitor for progression

Grade 2:

• Tocilizumab (IL-6 receptor antagonist):
  • Dose: 8 mg/kg IV over 1 hour (max 800 mg)
  • Repeat every 8 hours if no improvement (max 3-4 doses)
  • Onset: fever defervescence typically within 12-24 hours
• If no improvement within 24 hours, consider low-dose steroids:
  • Dexamethasone 10 mg IV q6h

Grade 3:

• Tocilizumab 8 mg/kg IV immediately
• Dexamethasone 10 mg IV q6h (or methylprednisolone 1-2 mg/kg IV q12h)
• Aggressive hemodynamic support:
  • Vasopressors: norepinephrine first-line
  • Invasive monitoring if multiple vasopressors required
• Respiratory support as needed

Grade 4:

• Tocilizumab 8 mg/kg IV immediately
• High-dose methylprednisolone 1000 mg IV daily OR dexamethasone 20 mg IV q6h
• ICU-level care:
  • Multiple vasopressors, invasive hemodynamic monitoring
  • Mechanical ventilation with lung-protective strategies
  • Renal replacement therapy if indicated
• Consider additional agents if refractory:
  • Siltuximab (IL-6 antagonist) 11 mg/kg IV if tocilizumab unavailable
  • Anakinra (IL-1 receptor antagonist) 100 mg SC q6-8h
  • Ruxolitinib (JAK1/2 inhibitor) emerging data for refractory CRS

Pearl: The "Tocilizumab Window"

Tocilizumab blocks IL-6 signaling but does not deplete CAR-T cells, allowing therapeutic efficacy to continue. However, tocilizumab blocks fever (via central IL-6 inhibition), which can mask infection. Any patient receiving tocilizumab must be on broad-spectrum antibiotics. Additionally, tocilizumab has a narrow effect—it won't treat concurrent neurotoxicity, which requires steroids.

Hack: Early Intervention Is Key

Don't wait for grade 3 CRS to administer tocilizumab. Studies show early tocilizumab (at grade 2) reduces severe CRS without compromising CAR-T efficacy. The ELIANA trial initially showed tocilizumab use in 77% of patients, but with earlier intervention protocols, severe CRS rates have dropped from 30% to <10%.

Oyster: The Steroid Conundrum

While steroids effectively treat CRS, there's theoretical concern about impairing CAR-T expansion and long-term efficacy. However, real-world data suggests that early, brief steroid courses (3-5 days) don't significantly compromise responses. The key is using the minimal effective dose and tapering rapidly once CRS resolves. Prolonged high-dose steroids (>7 days) should be avoided when possible.

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

ICANS, previously termed CAR-T-related encephalopathy syndrome (CRES), occurs in 30-60% of CAR-T recipients, with severe cases in 10-30%. Unlike CRS, ICANS pathophysiology is incompletely understood but involves blood-brain barrier disruption, cytokine penetration into CSF, and endothelial activation.

Clinical Features:

• Onset: typically 5-10 days post-infusion (median 7 days), often after or concurrent with CRS
• Encephalopathy: confusion, disorientation, decreased level of consciousness
• Aphasia: expressive more common than receptive; word-finding difficulty
• Impaired attention and concentration
• Seizures (10-20% of cases)
• Motor findings: tremor, myoclonus, ataxia (rare)
• Cerebral edema with herniation (rare but fatal)

ICE Score (Immune Effector Cell-Associated Encephalopathy):

A bedside 10-point assessment tool:

• Orientation (0-4 points): year, month, city, hospital
• Naming (0-3 points): three objects shown
• Following commands (0-1 point): "Show me two fingers"
• Writing (0-1 point): ability to write a sentence
• Attention (0-1 point): count backwards from 100 by 10

ASTCT ICANS Grading:

Grade 1:

• ICE score 7-9
• OR awakens spontaneously

Grade 2:

• ICE score 3-6
• OR awakens to voice

Grade 3:

• ICE score 0-2
• OR awakens only to tactile stimulus
• OR seizure (any, with rapid resolution)
• OR focal motor weakness

Grade 4:

• Any of:
  • Unresponsive or requires vigorous/painful stimuli to arouse
  • Seizures: status epilepticus or repetitive clinical/electrical seizures
  • Motor findings: deep focal weakness (e.g., hemiparesis)
  • Elevated ICP/cerebral edema
  • Depressed level of arousal with inability to perform ICE assessment

Diagnostic Workup:

• Brain MRI: typically normal, but may show PRES, white matter signal changes, or edema
• Lumbar puncture (if safe): typically shows elevated protein and pleocytosis
• EEG: if seizure suspected; may show diffuse slowing or epileptiform discharges
• Rule out infection, metabolic derangements, intracranial hemorrhage

Management of ICANS:

Prophylaxis:

• Levetiracetam 500-1000 mg BID starting day of CAR-T infusion and continuing for 30 days (standard at most centers)

Grade 1:

• Close neurological monitoring (q2-4h)
• ICE score assessments q8-12h
• Levetiracetam if not already on prophylaxis
• Consider dexamethasone 10 mg IV if symptoms persist >72 hours

Grade 2:

• Dexamethasone 10 mg IV q6h
• ICE score q4-6h
• Levetiracetam continuation
• MRI brain if not already obtained
• Consider ICU transfer if trending toward grade 3

Grade 3:

• ICU admission
• Dexamethasone 10-20 mg IV q6h (or methylprednisolone 1-2 mg/kg IV q12h)
• Continuous EEG monitoring
• Seizure management: benzodiazepines, additional AEDs as needed
• Consider methylprednisolone 1000 mg IV daily x 3 days if refractory

Grade 4:

• ICU with intensive monitoring
• High-dose methylprednisolone 1000-2000 mg IV daily
• Aggressive seizure management
• Intubation for airway protection if GCS ≤8
• ICP monitoring if cerebral edema present
• Consider:
  • Anakinra 100 mg SC q6h (emerging evidence)
  • Siltuximab if refractory
  • Hyperosmolar therapy (mannitol, hypertonic saline) for elevated ICP

Critical Distinction: CRS vs ICANS

CRS and ICANS frequently overlap but require different management. Tocilizumab treats CRS but does NOT treat ICANS (IL-6 antagonism may worsen neurotoxicity in some cases). Steroids treat both. Key distinguishing features:

Feature	CRS	ICANS
Fever	Always present	May or may not be present
Hypotension	Common	Uncommon
Hypoxia	Common	Uncommon
Encephalopathy	Rare	Defining feature
Treatment	Tocilizumab ± steroids	Steroids (NOT tocilizumab)

Clinical Hack: Don't Miss Concurrent ICANS

Altered mental status in a patient with CRS is ICANS until proven otherwise. If a patient with CRS develops confusion after tocilizumab, assume ICANS and add steroids immediately. Perform ICE score at every assessment—don't rely on "looks confused." Quantify it.

Pearl: ICANS Can Occur Without CRS

Approximately 10-15% of ICANS cases occur in the absence of CRS. Neurotoxicity is not simply a consequence of systemic inflammation—it has distinct pathophysiology. Always assess for ICANS independently of CRS status.

---

The "Hyperprogressive Disease" Paradox with Immunotherapy

Defining Hyperprogressive Disease (HPD)

While checkpoint inhibitors produce durable responses in some patients, a subset paradoxically experiences accelerated tumor growth compared to pre-treatment kinetics—a phenomenon termed hyperprogressive disease (HPD). This represents one of immunotherapy's most vexing challenges, occurring in approximately 9-29% of patients depending on definitions used.

Diagnostic Criteria:

Multiple definitions exist, creating controversy:

1. Tumor Growth Rate (TGR) Criteria:

   • TGR ratio >2 (comparing pre- and post-treatment tumor growth velocity)
   • Requires baseline imaging, pre-treatment imaging, and on-treatment imaging

2. RECIST-Based Criteria:

   • 50% increase in tumor burden within 2-3 months of starting immunotherapy

   • Compared to best response with previous therapy

3. Time to Treatment Failure (TTF):

   • TTF <2 months with rapid clinical deterioration

Clinical Characteristics of HPD:

• Rapid clinical decline: dramatic symptom worsening within weeks
• New metastatic sites appearing quickly
• Significant increase in tumor size (often >50% in <8 weeks)
• Shorter overall survival compared to patients with standard progressive disease
• Can occur with any checkpoint inhibitor (PD-1/PD-L1 or CTLA-4)

Potential Mechanisms

The mechanisms underlying HPD remain incompletely understood, with several hypotheses:

1. Aberrant Immune Cell Recruitment: Checkpoint blockade may recruit immunosuppressive cells (Tregs, myeloid-derived suppressor cells) to the tumor microenvironment in certain contexts, enhancing tumor growth rather than inhibiting it.

2. Fc-Mediated Depletion of Effector T Cells: PD-1 antibodies binding to PD-1+ T cells may trigger antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC), inadvertently depleting effector T cells. This hypothesis suggests anti-PD-L1 antibodies might have lower HPD risk, though clinical data don't consistently support this.

3. Oncogenic Pathway Activation: Certain tumor genomic alterations correlate with HPD:

• MDM2/MDM4 amplification (most strongly associated)
• EGFR alterations (particularly in lung cancer)
• Chromosome 11q13 amplification
• DNMT3A mutations

These alterations may promote aggressive tumor behavior when combined with immune perturbation.

4. Compensatory Checkpoint Upregulation: Blocking one checkpoint may lead to compensatory upregulation of alternative inhibitory pathways (e.g., TIM-3, LAG-3, TIGIT), resulting in T-cell exhaustion and tumor escape.

5. Tumor Flare Reaction: Similar to hormonal flare in prostate cancer with LHRH agonists, initial immune activation might paradoxically stimulate tumor growth through cytokine release (IL-6, IL-8) promoting angiogenesis and proliferation.

Risk Factors for HPD

Clinical Factors:

• Age >65 years (inconsistently associated)
• Poor performance status (ECOG ≥2)
• Multiple metastatic sites (≥3 organ systems)
• Liver metastases (associated with immunosuppressive microenvironment)
• Royal Marsden Hospital (RMH) prognostic score ≥2 (LDH elevated, albumin <35 g/L, liver mets)

Tumor Characteristics:

• High tumor burden
• Rapidly proliferative tumors (high Ki-67)
• MDM2/MDM4 amplification (seen in 15-20% of HPD cases)
• EGFR-mutant NSCLC (controversial; some series show increased risk)

Treatment Factors:

• Combination checkpoint inhibitor therapy may have higher HPD rates than monotherapy (needs validation)
• Prior therapies: heavily pre-treated patients may have higher risk

Clinical Recognition and Management

Early Warning Signs:

• Rapid clinical deterioration within 4-8 weeks
• New symptoms or significant worsening of existing symptoms
• Dramatic pain increase requiring opioid escalation
• Declining performance status
• Rising tumor markers

Imaging Assessment:

• Obtain first restaging scan at 6-8 weeks (earlier than typical 12-week interval if clinical concern)
• Compare tumor measurements to baseline AND to pre-treatment imaging if available
• Calculate tumor growth rate if serial imaging available
• PET-CT may help distinguish pseudoprogression from true HPD (HPD shows markedly increased FDG uptake)

Management Strategies:

1. Immediate Discontinuation:

   • Stop checkpoint inhibitor at first sign of HPD
   • Don't wait for confirmatory imaging if clinical deterioration is dramatic

2. Pivot to Alternative Therapy:

   • Chemotherapy (if chemotherapy-naive or long treatment-free interval)
   • Targeted therapy if actionable mutation present
   • Clinical trial with non-immunotherapy agent
   • Combination approaches (chemotherapy + immunotherapy) may overcome HPD in selected cases

3. Corticosteroids:

   • Some experts advocate for steroids (e.g., dexamethasone 4-8 mg daily) to dampen inflammatory tumor microenvironment
   • Limited evidence; theoretical benefit in cytokine-driven HPD

4. Salvage Immunotherapy:

   • Switching to alternative checkpoint inhibitor generally NOT recommended
   • Combination with other agents (chemotherapy, targeted therapy) may be considered in clinical trial setting

Oyster: Pseudoprogression vs HPD

Distinguishing pseudoprogression (immune infiltration causing apparent tumor enlargement, followed by response) from HPD is critical but challenging. Key differences:

Feature	Pseudoprogression	HPD
Timing	Usually 8-12 weeks	4-8 weeks
Clinical status	Stable or improving	Rapidly declining
Tumor markers	Stable or decreasing	Rising
FDG-PET	Increased or stable	Markedly increased
Subsequent imaging	Tumor shrinkage	Continued growth
Incidence	5-10%	9-29%

Pearl: The "Wait and Watch" Dilemma

When faced with radiographic progression at first restaging in a clinically stable patient, the clinician faces a difficult decision: continue immunotherapy (risking HPD) or switch therapy (risking discontinuation of effective treatment with pseudoprogression). Multidisciplinary discussion, tumor markers, PET imaging, and close clinical follow-up guide this decision. Generally, if performance status is declining or symptoms worsening, don't wait—change therapy.

Clinical Hack: Baseline Tumor Growth Kinetics Matter

If available, obtain tumor measurements from scans 3-6 months prior to immunotherapy initiation. Calculating pre-treatment tumor growth velocity allows more accurate assessment of whether post-treatment progression represents acceleration (HPD) versus natural disease progression.

---

Biomarkers for Response: PD-L1 Expression, Tumor Mutational Burden, and MSI-H

The Quest for Predictive Biomarkers

Despite revolutionary efficacy in some patients, checkpoint inhibitors benefit only a minority—response rates typically range from 15-45% depending on tumor type. The inability to reliably predict responders results in substantial toxicity and cost burden for non-responders. Multiple biomarkers have emerged, each with strengths and limitations.

PD-L1 Expression

Rationale: Tumor PD-L1 expression represents adaptive immune resistance—upregulation in response to IFN-γ from tumor-infiltrating lymphocytes. Theoretically, PD-L1+ tumors should benefit more from PD-1/PD-L1 blockade.

Testing Methods:

• Immunohistochemistry (IHC) on tumor tissue
• Multiple companion diagnostic assays: 22C3, 28-8, SP142, SP263 (not interchangeable)
• Scoring: Tumor Proportion Score (TPS) = % of viable tumor cells with membrane staining
• Combined Positive Score (CPS) = (PD-L1+ tumor cells + immune cells) / total tumor cells × 100

Clinical Utility:

NSCLC:

• Pembrolizumab monotherapy approved for PD-L1 TPS ≥50% (first-line)
• KEYNOTE-024: TPS ≥50% had 45% ORR with pembrolizumab vs 28% with chemotherapy
• TPS 1-49%: combination therapy preferred
• TPS <1%: checkpoint inhibitor efficacy reduced but not absent (10-15% still respond)

Head and Neck Squamous Cell Carcinoma:

• Pembrolizumab approved for CPS ≥1
• Higher CPS correlates with better outcomes, but responses occur across all CPS levels

Gastric Cancer:

• Pembrolizumab approved for CPS ≥1 (combined with chemotherapy)

Limitations of PD-L1 Testing:

1. Imperfect Correlation:

   • 10-15% of PD-L1 negative patients still respond
   • 40-50% of PD-L1 positive patients don't respond
   • PD-L1 expression is dynamic, changing with therapy and over time

2. Spatial and Temporal Heterogeneity:

   • PD-L1 expression varies within primary tumor, between metastases, and over time
   • Single biopsy may not represent overall tumor PD-L1 status

3. Technical Variability:

   • Different assays yield different results
   • Subjective interpretation by pathologists
   • Pre-analytical variables (fixation, processing) affect staining

4. Tumor Type Dependency:

   • Strong predictive value in NSCLC, less so in melanoma and RCC
   • Melanoma and RCC respond regardless of PD-L1 status

Pearl: PD-L1 Is Enrichment, Not Exclusion

PD-L1 should be viewed as an enrichment biomarker (identifying patients with higher response probability) rather than an exclusion biomarker (determining who should never receive immunotherapy). Clinical context, tumor type, and alternative therapies must be considered.

Tumor Mutational Burden (TMB)

Rationale: Higher somatic mutation burden generates more neoantigens—novel peptides resulting from tumor mutations. More neoantigens increase likelihood of immune recognition and response to checkpoint blockade.

Testing Methods:

• Whole exome sequencing (WES): gold standard, expensive, ~50 million bases
• Targeted panel sequencing: practical, ~1-2 million bases (e.g., FoundationOne CDx, MSK-IMPACT)
• Reported as mutations per megabase (mut/Mb)

Threshold:

• TMB-high (TMB-H) typically defined as ≥10 mut/Mb (panel-based) or ≥20 mut/Mb (WES)
• Optimal threshold varies by tumor type and assay

Clinical Evidence:

FDA Approval:

• Pembrolizumab approved (2020) for TMB-H (≥10 mut/Mb) tumors that have progressed on prior therapy and have no satisfactory alternative treatment options
• Based on KEYNOTE-158 trial: 29% ORR in TMB-H tumors vs 6% in TMB-low

CheckMate-227:

• First-line NSCLC: nivolumab + ipilimumab vs chemotherapy
• TMB ≥10 mut/Mb: improved PFS with immunotherapy (7.2 vs 5.5 months)
• TMB <10 mut/Mb: no PFS benefit

Tumor Types with High TMB:

• Melanoma (median ~15 mut/Mb)
• NSCLC (median ~8 mut/Mb, higher in smokers)
• Small cell lung cancer (~10 mut/Mb)
• Bladder cancer (~10 mut/Mb)
• MSI-H tumors (often >20 mut/Mb)

Limitations of TMB:

1. Imperfect Correlation:

   • Many TMB-H patients don't respond
   • Some TMB-low patients respond well
   • Correlation stronger for combination immunotherapy than monotherapy

2. Technical Challenges:

   • Panel-based TMB less accurate than WES
   • Variability between panels (different gene sets)
   • Blood-based TMB (liquid biopsy) less validated

3. Neoantigen Quality Matters:

   • Not all mutations generate immunogenic neoantigens
   • Clonality (shared among all tumor cells) affects response
   • TMB doesn't capture neoantigen presentation or T-cell repertoire

4. Cost and Accessibility:

   • Comprehensive genomic profiling expensive ($3,000-5,000)
   • Not universally available
   • Turnaround time 2-3 weeks

Oyster: The Blood TMB Story

Blood-based TMB (bTMB) from circulating tumor DNA offered promise as a non-invasive biomarker. However, the B-F1RST trial in NSCLC failed to validate bTMB ≥16 as predictive of pembrolizumab benefit, leading to FDA withdrawal of the bTMB indication. Plasma-based TMB remains investigational.

Microsatellite Instability-High (MSI-H) / Mismatch Repair Deficiency (dMMR)

Biological Basis: DNA mismatch repair (MMR) proteins (MLH1, MSH2, MSH6, PMS2) correct DNA replication errors. Deficiency in MMR (dMMR) leads to accumulation of mutations, particularly in microsatellites (repetitive DNA sequences), resulting in microsatellite instability (MSI).

MSI-H/dMMR tumors have:

• Very high TMB (often >50 mut/Mb)
• Abundant neoantigens
• Dense lymphocytic infiltration
• High PD-L1 expression

Testing Methods:

MSI Testing:

• PCR-based: analyzes 5 microsatellite markers (Bethesda panel)
• MSI-H: ≥2/5 markers unstable
• MSI-L: 1/5 unstable
• MSS: 0/5 unstable

MMR IHC:

• Evaluates MLH1, MSH2, MSH6, PMS2 protein expression
• dMMR: loss of ≥1 MMR protein
• pMMR: intact expression of all four proteins

Next-Generation Sequencing:

• Can detect MSI from panel sequencing data
• Good concordance with PCR-based testing

Epidemiology:

• Colorectal cancer: 15% of stage II-III, 4% of metastatic
• Endometrial cancer: 20-30%
• Gastric cancer: 10-20%
• Rare in most other tumor types (<5%)
• Germline MMR mutations (Lynch syndrome) account for 3% of MSI-H cancers

Clinical Efficacy:

Landmark FDA Approval (2017):

• Pembrolizumab: first tissue/site-agnostic cancer approval based on MSI-H/dMMR status
• KEYNOTE-016/164/012/158 pooled analysis: 39.6% ORR, 78% disease control rate
• Responses remarkably durable (median not reached at 4+ years)

CheckMate-142:

• Nivolumab in MSI-H/dMMR metastatic colorectal cancer: 31% ORR
• Nivolumab + ipilimumab: 55% ORR, 71% disease control rate
• Superior to historical chemotherapy controls

MSI-H as a Predictive Biomarker:

MSI-H/dMMR status is the strongest predictive biomarker for checkpoint inhibitor efficacy, showing benefit across tumor types:

Tumor Type	MSI-H Frequency	Checkpoint Inhibitor ORR
Colorectal	4% (metastatic)	40-55%
Endometrial	25-30%	45-50%
Gastric	10-20%	50-60%
Small bowel	10-15%	35-40%
Ovarian	<5%	40-50%

Clinical Hack: Test All Advanced Colorectal Cancers

Given the dramatic efficacy of immunotherapy in MSI-H/dMMR mCRC and poor prognosis with chemotherapy alone, NCCN guidelines recommend universal MSI/MMR testing in all stage IV colorectal cancers at diagnosis. Consider first-line immunotherapy for MSI-H/dMMR mCRC given superior outcomes and lower toxicity compared to chemotherapy.

Pearl: MSI-H Predicts LACK of Benefit from Fluoropyrimidine Adjuvant Therapy

In stage II colon cancer, MSI-H/dMMR tumors have better prognosis but don't benefit from 5-FU-based adjuvant chemotherapy (potentially harmful). However, in stage III, benefit is less clear. MSI-H status guides not only immunotherapy decisions but also chemotherapy selection.

Emerging and Investigational Biomarkers

Tumor-Infiltrating Lymphocytes (TILs):

• "Hot" tumors (dense CD8+ T-cell infiltration) respond better than "cold" tumors
• Challenges: quantification subjective, requires tumor tissue, no standardized scoring

Interferon-Gamma (IFN-γ) Gene Signature:

• Elevated IFN-γ pathway gene expression predicts response
• Composite scores (e.g., Tumor Inflammation Signature) under development
• Requires RNA sequencing, not widely available

Gut Microbiome:

• Emerging data suggest microbiome composition influences immunotherapy response
• Firmicutes/Bacteroidetes ratio, Akkermansia muciniphila abundance associated with better outcomes
• Fecal microbiota transplantation from responders to non-responders under investigation

Circulating Tumor DNA (ctDNA):

• Early decreases in ctDNA levels correlate with response
• May allow earlier assessment than radiographic imaging
• Standardization and validation ongoing

Immune Contexture:

• Spatial arrangement of immune cells relative to tumor (Immunoscore)
• Quantifies CD3+ and CD8+ T cells in tumor center and invasive margin
• Prognostic in colorectal cancer; predictive utility under investigation

Combining Biomarkers: The Future

Single biomarkers have limited predictive accuracy. Multiparameter approaches integrating PD-L1, TMB, MSI, gene expression signatures, and immune contexture may improve patient selection. Machine learning algorithms analyzing comprehensive genomic and transcriptomic data show promise but require validation.

The ideal biomarker strategy balances:

• Predictive accuracy: sensitivity and specificity for response
• Accessibility: cost, tissue requirements, turnaround time
• Actionability: informing treatment decisions
• Tumor type applicability: universal vs histology-specific

Oyster: Biomarker Combinations in Clinical Trials

Multiple trials are exploring biomarker-driven strategies:

• SWOG S1800A: PD-L1/TMB-stratified treatment in NSCLC
• TAPUR: TMB-guided basket trial across tumor types
• POD1UM: PD-L1-stratified first-line therapy in NSCLC

Results will refine our understanding of optimal biomarker utilization.

---

Practical Considerations for the Internist and Intensivist

Pre-Treatment Assessment

Before initiating checkpoint inhibitors or CAR-T therapy, comprehensive baseline evaluation is essential:

Laboratory Testing:

• CBC, CMP, LFTs
• TSH, free T4
• Morning cortisol, ACTH
• Inflammatory markers (CRP, ESR) for baseline
• Hepatitis B/C serology, HIV (CAR-T requirement)

Imaging:

• Baseline CT chest/abdomen/pelvis
• Brain MRI if indicated by tumor type
• Consider PET-CT for response assessment planning

Functional Assessment:

• ECOG performance status
• Pulmonary function tests (if baseline lung disease)
• Cardiac evaluation (echo/EKG) if CAR-T planned or cardiac risk factors

Patient Education:

• irAE symptoms to watch for
• Importance of early reporting
• Steroid card if high-risk endocrinopathy
• Emergency contact information

Monitoring During Therapy

Immune Checkpoint Inhibitors:

• Clinical assessment before each infusion
• Labs: CBC, CMP, LFTs, TSH q6-12 weeks
• Imaging: typically q12 weeks (q6-8 weeks if clinical concern)
• Symptoms: daily patient self-monitoring

CAR-T Therapy:

• Inpatient monitoring ≥7 days post-infusion at experienced center
• Vital signs q4-6h for first 14 days
• Daily CRS/ICANS assessments
• Labs: CBC, CMP, LFTs, CRP, ferritin daily x 14 days
• Tocilizumab and dexamethasone immediately available

When to Consult Specialists

Oncology: Always involved; first call for any immune-related toxicity

Gastroenterology: Grade 2+ colitis, GI bleeding, steroid-refractory diarrhea

Pulmonology: Any pneumonitis, bronchoscopy for diagnosis

Endocrinology: Thyroid dysfunction, suspected hypophysitis, adrenal insufficiency, diabetes

Cardiology: Troponin elevation, arrhythmia, heart failure symptoms

Neurology: Any neurological symptoms (weakness, seizures, encephalopathy)

Dermatology: SJS/TEN, severe rash, bullous lesions

Rheumatology: Inflammatory arthritis, myositis, vasculitis

The Role of Corticosteroids: Principles

1. Early is better than late: Don't delay steroids hoping for spontaneous resolution in grade ≥2 irAEs
2. Dose matters: Under-dosing leads to prolonged toxicity; use adequate doses
3. Taper slowly: Rapid tapers risk rebound inflammation; taper over ≥4-6 weeks for serious irAEs
4. Don't fear steroids: Brief steroid courses (<1 week) don't significantly impair immunotherapy efficacy
5. Concurrent prophylaxis: PCP prophylaxis (TMP-SMX) and PPI for patients on prolonged high-dose steroids

Documentation and Communication

Steroid Card: All patients on chronic steroids should carry a card or wear medical alert jewelry indicating:

• Steroid-dependent adrenal insufficiency
• Stress dosing requirements
• Emergency contact information

Transition of Care: When patients transfer between facilities or providers, critical information must be communicated:

• Immunotherapy agent and dates
• History of irAEs and treatments
• Current immunosuppression regimen
• Baseline organ function
• Endocrine replacement needs

---

Conclusion

Cancer immunotherapy represents one of medicine's greatest advances, fundamentally altering the natural history of previously fatal malignancies. Yet this revolution demands that internists and critical care physicians develop expertise in immunology, novel toxicities, and complex management paradigms.

Key principles for the practicing clinician:

1. Immunotherapy responses differ fundamentally from chemotherapy: delayed responses, pseudoprogression, and durable activity characterize checkpoint inhibitors.

2. irAEs can affect any organ system at any time: maintain high clinical suspicion, grade systematically, and intervene early with immunosuppression.

3. CRS and ICANS are distinct syndromes requiring different management: tocilizumab for CRS, steroids for ICANS—know the difference.

4. Hyperprogressive disease is real and devastating: recognize early warning signs and don't hesitate to discontinue immunotherapy in rapidly deteriorating patients.

5. Biomarkers inform but don't dictate: PD-L1, TMB, and MSI-H enrich for responders but shouldn't absolutely exclude patients from therapy.

6. Multidisciplinary collaboration is essential: no single specialist can manage these complex patients alone.

As immunotherapy expands to earlier disease stages, additional indications, and combination regimens, the internist's role becomes increasingly critical. Familiarity with these concepts—from checkpoint biology to cytokine storms—transforms academic knowledge into lifesaving clinical acumen.

The patient in your ICU with fulminant colitis, the emergency department patient with altered mental status post-CAR-T, the clinic patient with fatigue and hypotension—these scenarios demand prompt recognition, systematic evaluation, and evidence-based intervention. Master these principles, collaborate with specialists, and remain vigilant for novel toxicities. In doing so, you'll optimize outcomes for patients benefiting from this remarkable therapeutic revolution.

---

References

1. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345-1356.

2. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-1833.

3. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-1768.

4. Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2017;28(suppl_4):iv119-iv142.

5. Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721-1728.

6. Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25(4):625-638.

7. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.

8. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-448.

9. Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017;23(8):1920-1928.

10. Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018;4(11):1543-1552.

11. Kato S, Goodman A, Walavalkar V, et al. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23(15):4242-4250.

12. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500-2501.

13. Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational burden predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202-206.

14. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093-2104.

15. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753-3758.

16. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-413.

17. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182-1191.

18. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847-856.

19. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275-287.

20. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-1550.

21. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521-2532.

22. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-1813.

23. Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95.

24. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51-60.

25. Abu-Sbeih H, Ali FS, Alsaadi D, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer. 2018;6(1):142.

26. Johnson DB, Friedman DL, Berry E, et al. Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center. Cancer Immunol Res. 2015;3(5):464-469.

27. Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017;50(2):1700050.

28. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709-717.

29. Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol. 2017;74(10):1216-1222.

30. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749-1755.

31. Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755-1764.

32. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173-182.

33. Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99(11):4078-4085.

34. Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021;17(7):389-399.

35. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-168.

36. Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739-748.

37. Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133(7):697-709.

38. Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404-1419.

39. Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958-971.

40. Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295-2306.

41. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85-96.

42. Kadauke S, Myers RM, Li Y, et al. Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial. J Clin Oncol. 2021;39(8):920-930.

43. Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322-3331.

44. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45-56.

45. Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705-716.

46. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314-324.

47. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491-502.

48. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-2028.

49. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-1639.

50. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856-1867.

---

Key Clinical Pearls Summary

Checkpoint Inhibitors:

• Responses may be delayed; pseudoprogression occurs in 5-10% of patients
• Consider continuing therapy through initial "progression" if patient clinically stable
• Duration of therapy remains uncertain; some maintain responses after 2 years of treatment
• Combination CTLA-4 + PD-1 increases efficacy but also toxicity (59% grade 3-4 irAEs)

irAE Management:

• Grade ≥2 irAEs require immunosuppression; don't delay steroid initiation
• Colitis: CMV reactivation occurs in 20% of steroid-refractory cases
• Pneumonitis: requires slow steroid taper (4-8 weeks minimum) to prevent rebound
• Endocrinopathies: screen early and often; most are permanent requiring lifelong replacement
• Myocarditis: highest mortality (25-50%); check troponin if any cardiac symptoms
• Always check morning cortisol in patients with vague symptoms before assuming progression

CAR-T Therapy:

• CRS and ICANS are distinct: tocilizumab for CRS, steroids for ICANS
• Early tocilizumab (at grade 2 CRS) reduces severe CRS without impairing efficacy
• Perform ICE score at every assessment; quantify neurologic status objectively
• ICANS can occur without CRS; always assess independently
• Levetiracetam prophylaxis standard for 30 days post-CAR-T infusion

Hyperprogressive Disease:

• Occurs in 9-29% of patients receiving checkpoint inhibitors
• Warning signs: rapid clinical deterioration within 4-8 weeks, new metastatic sites
• MDM2/MDM4 amplification strongest genomic association
• First restaging at 6-8 weeks if clinical concern (don't wait for 12 weeks)
• Discontinue immunotherapy immediately if HPD suspected

Biomarkers:

• PD-L1 is enrichment biomarker, not exclusion marker (PD-L1 negative patients can respond)
• TMB-H (≥10 mut/Mb) predicts better response, especially with combination therapy
• MSI-H/dMMR strongest predictive biomarker (40-55% ORR across tumor types)
• Test all metastatic colorectal cancers for MSI/MMR at diagnosis
• Single biomarkers have limited accuracy; multiparameter approaches emerging

Critical Actions:

• Educate patients about irAE symptoms before starting therapy
• Maintain high index of suspicion for irAEs throughout and after treatment
• When in doubt, check inflammatory markers and consider steroid trial
• Early multidisciplinary consultation saves lives
• Document steroid-dependent adrenal insufficiency clearly for all providers

---

Abbreviations

ACTH - Adrenocorticotropic hormone
ADL - Activities of daily living
APC - Antigen-presenting cell
ARDS - Acute respiratory distress syndrome
ASTCT - American Society for Transplantation and Cellular Therapy
BAL - Bronchoalveolar lavage
BCMA - B-cell maturation antigen
CAR - Chimeric antigen receptor
CMP - Comprehensive metabolic panel
COP - Cryptogenic organizing pneumonia
CPS - Combined positive score
CRP - C-reactive protein
CRS - Cytokine release syndrome
CTCAE - Common Terminology Criteria for Adverse Events
CTLA-4 - Cytotoxic T-lymphocyte antigen-4
ctDNA - Circulating tumor DNA
DKA - Diabetic ketoacidosis
DLBCL - Diffuse large B-cell lymphoma
dMMR - Mismatch repair deficient
ECOG - Eastern Cooperative Oncology Group
FDA - Food and Drug Administration
HPD - Hyperprogressive disease
ICANS - Immune effector cell-associated neurotoxicity syndrome
ICI - Immune checkpoint inhibitor
ICE - Immune effector cell-associated encephalopathy
ICU - Intensive care unit
IFN-γ - Interferon gamma
IHC - Immunohistochemistry
IL - Interleukin
irAE - Immune-related adverse event
IVIG - Intravenous immunoglobulin
LDH - Lactate dehydrogenase
MHC - Major histocompatibility complex
MMR - Mismatch repair
MRI - Magnetic resonance imaging
MSI - Microsatellite instability
MSI-H - Microsatellite instability-high
NCCN - National Comprehensive Cancer Network
NSCLC - Non-small cell lung cancer
NSIP - Non-specific interstitial pneumonia
ORR - Overall response rate
OS - Overall survival
PCR - Polymerase chain reaction
PD-1 - Programmed death-1
PD-L1 - Programmed death ligand-1
PET - Positron emission tomography
PFS - Progression-free survival
pMMR - Mismatch repair proficient
PRES - Posterior reversible encephalopathy syndrome
RCC - Renal cell carcinoma
RECIST - Response Evaluation Criteria in Solid Tumors
RMH - Royal Marsden Hospital
scFv - Single-chain variable fragment
SIRS - Systemic inflammatory response syndrome
SJS - Stevens-Johnson syndrome
TCR - T-cell receptor
TEN - Toxic epidermal necrolysis
TGR - Tumor growth rate
TIL - Tumor-infiltrating lymphocyte
TMB - Tumor mutational burden
TMB-H - Tumor mutational burden-high
TNF - Tumor necrosis factor
TPS - Tumor proportion score
Treg - Regulatory T cell
TSH - Thyroid-stimulating hormone
TTF - Time to treatment failure
WES - Whole exome sequencing

---

Author Contributions and Disclosures

This review article is intended for educational purposes for postgraduate trainees in internal medicine and critical care. The authors have no conflicts of interest to disclose. No funding was received for this work.

---

Correspondence

For questions or comments regarding this review, readers are encouraged to consult the referenced primary literature and updated clinical practice guidelines from ASCO, ESMO, NCCN, and SITC.

---

Published: 2025

Target Audience: Postgraduate trainees and practicing physicians in internal medicine, critical care, and hospital medicine